

0040-4020(94)00786-1

Synthesis of Medium-Sized Lactones by the Copper(I)Chloride/2,2'-Bipyridine-Catalyzed Cyclization of Di- and Trichloroacetates

Frank 0. H. Pirrung, Henk Hiemstra' and W. Nice Speckamp'

Laboratory of Organic **Chemistry, Univemity of Amstedam. Nieuwe Achtergracht 129,** 1018 WS Amsterdam, The Netherlands

Bernard Kaptein and Hans E. Schoemaker

DSM Research, P. O. Box 18, 6160 MD Geleen, The Netherlands

Abstract. Medium-sized lactones (eight- to eleven-membered rings) are efficiently formed by Cu(bpy)C1 catalyzed cyclization of various alkenyl di- and trichloroacetates at temperatures between 80
and 190 °C in 1,2-dichloroethane or benzene as solvents. The mechanism of the alkene addition reaction is best understood as a chlorine atom transfer process through radical type intermediates. Exclusive endo-cyclization is observed in all cases. Ten and eleven-membered lactones are only accessible by the 'rigid chain' approach, in which an alkyne or alkene function is incorporated in the chain conne reaction centres, thus reducing the flexibility of the molecule.

INTRODUCTION

The synthesis of medium-sized lactones (8- to 12-membered ring systems) has recently received **considerable attention1 because these lactones occur in the basic structure of various natural products with interesting biological** activities.2 Among the methods developed, radical based techniques for the formation of lactones and other heterocycles are scarce.³ The so-called radical transfer process mediated by transition metal catalysts is successfully applied for the formation of S-membered lactones and lactams from ally1 di- and trichloroacetates and amides by a radical exo -cyclization onto a double bond.⁴ A number of C-C bond formations of this type is described using $RuCl₂(PPh₃)₃,^{4a,5b} CuCl$ in acetonitrile⁶ and Cu(bpy)Cl.^{4b} The successful Cu(I) and Ru(II) catalyzed exo-cyclizations of allyl chloroacetates 1 and 2 to the 5-membered lactones 3 and 4 are representative examples: $4a$

> 20 _{CRCl₂} Ö $Cu(I)$ or $Ru(II)$ cl $\bigcup_{i=1}^{n}$ R=H **1 * ;t(-** R=H 3 R=C12 O 0 R=Cl4

In addition, Fe and Mo complexes are known to catalyze the formation of C-C bonds between activated halogen compounds and alkenes.^{4a,5b} This type of reaction is applied in industrial processes to produce herbicides of general application.7

We set out to examine the activity of the Cu(bpy)Cl catalyst towards ω -alkenyl chloroacetates to form 8-, 9-, lo- and 1 l-membered lactones in view of our earlier successful work on intramolecular additions of glycine derived radicals by this catalyst.⁸ Our strategy is outlined in Scheme 1. We concentrated on the use of di- and trichloroacetates of various co-alkenols. readily obtained by simple eskrification via the acid chlorides. 'Ihe esters were then treated with the Cu-catalyst under an appropriate set of conditions to yield cyclization products.⁹

Scheme 1. Synthetic strategy

In this paper we report on the formation of 8- to 11-membered lactones by Cu(bpy)Cl catalyzed atom transfer cyclization of co-alkenyl di- and trichloroacetates. We show that 8- and 9-membered rings are readily accessible from various unsubstituted and methyl- or phenyl-substituted alkenyl esters. For the larger rings it appears necessary to introduce a rigid element into the functional group connecting chain to reduce its flexibility.

RESULTS

Synrhesis of the cyclization precursors

The di- and trichloroacetates 5-34 (Tables 1,2 and 4) were prepared by esterification of the alkenols by using 1.0 to 1.5 equiv of di- or trichloroacetyl chloride and 2.0 equiv of Et₃N in CH₂Cl₂ at 0 °C for 2 h.¹⁰ The products could be easily isolated and purified by flash chromatography and were obtained in high yields (Tables 1, 2 and 4).

Many of the alkenols were commercially available. The remaining alkenols were synthesized as follows: 6-Hepten-1-ol (entries 13, 14, Table 1) was prepared from 6-heptenoic acid by LiAlH4 reduction (100%). Racemic 1-phenyl- and 1-methyl-4-penten-1-ol¹¹ (entries 1, 2, Table 2), as well as 2-methyl-5-hexen-2-ol¹² (entry 3, Table 2) were obtained by Grignard addition of 1-bromo-3-butene to benzaldehyde, acetaldehyde or acetone, respectively. 2,2-Dimethyl-4-penten-1-ol¹³ (entries 4, 5, Table 2) was prepared by LiAlH₄ reduction of the commercially available 2,2dimethyl-4-pentenal. Following a literature procedure 3.3~dimethyl-4-pentenl-0114 (entries 6, 7, Table 2) was prepared by Claisen orthoester rearrangement of 3-methyl-2-buten-l-01, followed by reduction of the resulting ethyl ester by LiAlH₄. 4-Methyl-4-penten-1-ol¹⁵ (entries 8, 9, Table 2) was obtained by a Wittig reaction on ethyl levulinate, followed by LiAlH₄ reduction. 5-Methyl-4-hexen-1-ol¹⁶ (entries 12, 13, Table 2) was prepared by copper mediated alkylation of ethyl acetate with 1-bromo-3-methyl-Z butene and subsequent reduction of the resulting ethyl ester by LiAlH4. 6-Hepten-3-yn-1-ol (entries 1, 2, Table 4) and 7-octene-4-yn-l-01 (entries 5,6, Table 4) were prepared by Cu-catalysed alkylation of 3-butyn-l-01 and 4-pentyn-1-ol with allyl bromide.¹⁷ Reduction to (Z) -hepta-3,6-dien-1-ol (entries 3, 4, Table 4) was accomplished by NaBH₄ with catalytic PdCl₂ in polyethylene glycol 200 at -10 $^{\circ}$ C.¹⁸

Cyclization of substrares with unsubstimted chains

The 3-butenyl chloroacetates 5 and 6 were treated with 0.3 equiv of Cu(bpy)Cl in refluxing 1,2 dichloroethane (DCE, bp 83.5 °C) for 18 h (entries 1 and 2, Table 1). However, their cyclization in either the 6exo or the 7-endo mode failed completely. Only telomerization products could be detected in the crude reaction mixtures. The failure of these cyclizations might be related to the unwillingness of the ester group to adopt the s $trans\text{-conformation during the cyclization reaction}$. $3d,19$

entry	precursor (yield from the alcohol)	conditions [*]	products, yield (diastereomeric ratio cis:trans)		
	CRCI2				
1	$R=H 5(98%)$	Cu*, DCE, reflux, 18 h	telomers		
$\overline{2}$	$R = Cl 6 (87%)$	Cu*, DCE, reflux, 18 h	telomers		
			.CI o ci R		
3	$R=H 7(100%)$	Cu*, DCE, reflux, 18 h	35a,b 75% $(70:30)^b$		
4		Cu*, PhH, reflux, 18 h	35a,b 92% (70:30) ^b		
5		Cu*, PhH, 140 °C, 2 h	35a,b 90% (70:30) ^b		
6	$R = C1$ 8 (100%)	Cu*, DCE, reflux, 18 h	38 60%		
7		Cu*, PhH, reflux, 20 h	38 39%		
8		Cu*, DCE, 130 °C, 2.5 h	38 58%		
9		CuCl/MeCN, 130 °C, 3 d	38 24% (63% of s.m.)		
10		RuCl ₂ (PPh ₃) ₃ , PhH, 140 °C, 5 h	38 21%		
			C. СI R		
11	$R=H$ 9 (85%)	Cu*, DCE, reflux, 18 h	39a,b 57% $(70:30)^b$		
12	$R=Cl$ 10 (86%)	Cu*, DCE, 190 °C, 2 h	41 59%		
	CRCI2				
13	R=H 11 (94%)	Cu*, DCE, reflux	telomers		
14	$R = C1$ 12 (66%)	Cu*, DCE, reflux	telomers		
		CHCI ₂			
15	13 (85%)	Cu*, DCE, reflux	telomers		
16 17	R=H 14 (87%) $R = C1$ 15 (92%)	Cu*, DCE, reflux to 190 °C Cu*, DCE, reflux to 190 °C	starting material and telomers starting material and telomers		

Table 1: Cyclizations of substrates with unsubstituted chains

a) Cu*: 0.3 equiv of Cu(bpy)CI was employed. b) insegarable mixture.

On the contrary, 4-pentenyl dichloroacetate (7) cyclized under identical reaction conditions to give the 8membered lactone 35 in 75% yield (entry 3, Table 1) as an inseparable (by column chromatography) mixture of diastereomers (70:30). The major isomer 35a was assigned by ¹H NMR as the thermodynamically favoured cis -isomer for an 8-membered lactone in a crown conformation.²⁰ The cyclization yield could be improved to 92% by using refluxing benzene as solvent (entry 4). Alternatively, at higher temperature and with shorter reaction time (140 'C. sealed tube, 2 h, entry 5) an almost identical yield (90%) was obtained. Other solvents could be used (THF, acetonitrile, CH₂Cl₂, acetone, toluene, xylene), but led to much lower yields (<50%). When ethers (THF, diglyme) were used, the monochloroacetate (22-26%) could be detected in the reaction mixture. This latter product most probably arises if the rate of hydrogen abstraction from the solvent can compete with cyclization. 5^b

The structure of 35 was proven beyond doubt by reduction of the diastereomeric mixture to the known unsubstituted derivative 36²² (60%) with HSnBu₃/AIBN (Scheme 2). Treatment of 35 with Zn dust in acetic acid²³ led to the monochloro derivative 37 (Scheme 2).

Scheme 2. Reduction of lactones

The trichloroacetate 8 (entry 6, Table 1) cyclized to the 8-membered lactone 38 in 60% isolated yield, when treated with 0.3 equiv of the catalyst in refluxing DCE for 18 h. Alternatively the reaction was complete in 2.5 h at 130 'C in DCE (58%, entry 8). In all cases, significant amounts of telomers were formed. This problem could not be suppressed by applying higher dilution.

Substrate 8 was also treated with 0.3 equiv of CuCl in acetonitrile at 130 °C for 3 d without the bipyridine ligand (entry 9). This procedure led to only 24% of the desired 8-membered lactone 38 with 63% of starting ester remaining, showing the importance of the bipyridine ligand in the catalyst for the enhancement of the reaction rate. Similarly, 8 was treated with RuCl₂(PPh₃)₃ (entry 10), producing only 21% of 38, together with an extensive amount of telomeric side products. This Ru-catalyst has heen used for the formation of 5 membered rings from trichloroacetates.⁵ The present result indicates that it is not suited for the efficient formation of medium-sired lactones.

Reaction of the 5-hexenyl chloroacetates 9 and 10 with Cu(bpy)Cl (entries 11 and 12) afforded the corresponding 9-membered rings. The dichloroacetate 9 reacted in a refluxing solution of DCE for 20 h to 39 in 57% yield as an inseparable mixture of the two diastereomers 39a and **39b in** a *cis:trans* ratio of 70:30. Lactone 39 was treated with HSnBu₃/AIBN to yield the parent nine-membered lactone 40²² (Scheme 2). Again, exclusive *endo-cyclization occurred*, no trace of the alternative 8-exo product being detectable. Similarly, the cyclization reaction of the corresponding trichloroacetate 10 proceeded at 190 °C in 2 h to give lactone 41

(59%) as a single mgioisomer. At 80 'C in DCE for 18 h, comparable yields could be obtained. In the **case of** nine-membered rings more telomeric material was formed than in the case of eight-membered systems.

Next, we subjected the heptenyl chloroacetates 11 and 12 to our cyclization conditions (entries 13 and 14). In both cases only telomerization products were formed by treatment with Cu(bpy)Cl in DCE at reflux. Undecenyl dichloroacetate 13 (entry 15) also led exclusively to telomers. As a rationale for these results, we assume that unfavourable entropy effects are more important when the chain is elongated. This conclusion can also be inferred from the larger amount of telomers formed in the case of nine-membered lactones.

To complete this study of unsubstituted chains we subjected the 4-pentynyl chloroacetates 14 and 15 to our standard conditions (entries 16 and 17). The starting materials were left untouched or gave telomeric material, showing that alkynes are unsuitable substrates for this type of cyclixation.

Cyclization of substrates with alkyd substituted chains

In order to further study the scope of the cyclixation reaction methyl- and phenyl-substituted pentenyl acetates were used. The presence of **substituents** on the alkyl chain of the cyclization precursor should affect the conformation of the cyclixation substrates, and thus the cyclixation process.

Dichloroester 16 cyclized to eight-membered lactone 42 in 68% (see Table 2, entry 1) as a non-separable mixture of three diastereomers in the ratio of 70:20:10. The *cis*-dichloro isomer 42a was the major compound as implied from the characteristic signals of the C-4 methylene group in the ¹H NMR spectrum (vide infra and see Table 3). For this ring closure a reaction temperature of 130 'C was necessary. At lower temperatures the starting material remained unchanged.

Figure 1. Crystal structure of $43a$
(Chem $3D^{TM}$ view)

The phenyl-substituted dichloroacetate 17 (entry 2). upon treatment at 180 'C for 2 h with Cu(bpy)Cl. cyclixed to a 68:18:13 mixture of diastereomers of the eight-membered lactone 43 in 51% yield. No reaction took place at 80 °C. No seven-membered product by exe-closure was detected. The major isomer 43a could be obtained pure by crystallixation from the product mixture (mp 7 l-76 'C) and was subjected to an X-ray analysis²⁴ (Figure 1, Table 5). The crystal structure determination proved the oxocan-2-one skeleton and revealed the cis-relationship between the chlorine substituents. The phenyl substituent was found *trans* with respect to the two chlorine substituents. The plane of the aromatic ring is oriented perpendicular with respect to a plane through the eight-membered lactone ring. The

lactone ring adopts a chair-chair (or crown) conformation and an s -trans-lactone geometry (dihedral angle 142 $^{\circ}$, Figure 2).²⁰ In this way the three substituents can adopt *pseudo*-equatorial positions, which reflects the thermodynamically most stable product.

The 1,1-dimethyl substituted precursor 18 (entry 3) failed to cyclize to the desired lactone product, even at high temperatures (180 'C) for several hours. The harsh conditions necessary for the 1-substituted precursors and the failure $O - \left($ *s-cis* of the cyclization of 18 points to steric hindrance by these substituents during the ring closure. Figure 2. Ester geometries²⁵ $\frac{1}{2}$ Figure 2. Ester geometries²⁵

Following the above procedure the 2.2-dimethyl substituted dichloroacetate 19 afforded 81% of a diastereomeric mixture (75:25) of the eight-membered lactone 44 (entry 4). The mixture of diastereomers of lactone 44 was treated with HSnBu3/AIBN to yield the 7,7-dimethyl substituted oxocan-2-one 45 (Scheme 2). The cis-isomer 44a could be obtained pure by crystallization and was subjected to X-ray analysis^{9a,24} (Figure 3, Table 5). The data show that the eight-membered ring has a crown conformation an s-trans-lactone geometry (dihedral angle 143°) and *pseudo*-equatorial positions of the *cis*-chlorine atoms.

The corresponding trichloroacetate 20 gave the eight-membered lactone 46 (67%) as a crystalline product (entry 5). The X-ray structure of this compound²⁴ (Figure 4, Table 5) shows a crown conformation of the eight-membered ring almost identical to the corresponding dichlorolactone (Figure 3). The C-5 chlorine atom adopts the *pseudo-equatorial position and the ring an s-trans-lactone geometry (dihedral angle 140[°]).*

The ¹H NMR data of the cis-isomers 35a, 39a, 42a, 43a and 44a of the lactones exhibit a striking resemblance, especially in the splitting pattern of the C-4 methylene hydrogens (see Table 3).

compound	$H-3$ ppm ^a	H-4ax ppm ^a	H-4eq ppm ^a
35a	4.48 (dd, 6.2, 11.5)	2.57 (ddd, 11.1, 11.5, 14.0)	2.91 (ddd, 1.2, 5.8, 14.0)
35 _b	4.68 (dd, $4.4, 6.5$)	2.63 (ddd, $2.8, 6.6, 14.1$)	2.88 (ddd, 4.4, 9.1, 14.1)
39a	4.46 (dd, 6.0, 11.8)	2.42 (ddd, 9.0, 11.8, 14.3)	2.75 (ddd, 1.8, 5.8, 14.4)
39b	4.55 (dd, 3.2, 5.6)	2.62 (ddd, 3.2, 5.6, 15.4)	2.72 (ddd, 3.2, 8.0, 15.4)
42a	4.50 (dd, 6.5, 11.5)	2.55 (dt, 11.3, 13.6)	2.90 (dd, 6.4, 13.5)
43a	4.62 (dd, 6.5, 11.2)	2.66 (dt, 11.4, 13.6)	3.01 (dd, 6.4, 13.6)
44a	4.52 (dd, 6.4, 11.7)	2.47 (dt. 11.5, 13.4)	2.90 (dd, 6.3, 13.4)
44 b	$4.50 - 4.53$ (m)	$2.70 - 2.75$ (m)	$2.70 - 2.75$ (m)
47a	4.55 (dd, 5.4, 12.0)	2.45 (ddd, 7.9, 12.0, 15.3)	2.71 (ddd, 1.0, 5.4, 15.3)
47b	4.44 (dd, $3.0, 5.1$)	2.60 (ddd, 4.7, 7.1, 15.2)	2.70 (ddd, 1.7, 8.9, 15.2)
49a	4.28 (dd, $4.7, 11.4$)	2.92 (dd, 11.5, 13.8)	2.67 (dd, $4.7, 13.9$)
49b	4.74 (dd, $4.2, 9.9$)	2.56 (dd, 9.9, 14.6)	2.71 (dd, 4.2, 14.6)

Table 3: Selected ${}^{1}H$ NMR data of H-3, H-4ax and H-4eq of chloro substituted oxocanones

a) measured in CDCl₃, *J* in Hz.

The pseudo-axial H-4 is found around 2.50 ppm as a double triplet or ddd with a geminal coupling of ca. 13.5 Hz and two vicinal couplings of ca. 11 Hz. The *pseudo-equatorial* H-4 usually shows a double doublet at 2.70-2.90 ppm with the geminal coupling of ca. 13.5 Hz and one vicinal coupling of ca. 6 Hz with H-3 (alternatively a ddd with an extra small vicinal coupling with H-5 of ca. 1.5 Hz). Furthermore H-3 is a

Table 2: Cyclizations of substrates with alkyl substituted chains

Table 2 (continued)

a) 0.3 equiv of Cu(bpy)Cl was employed. b) **inseparable mixture.**

characteristic double doublet around 4.50 ppm. In the C-3/C-5 fruns-isomers (e.g. **35b, 39b** and **44b) the** signals of the two C-4 hydrogens are less separated from each other. The vicinal couplings in the cis-isomers were in good agreement with the data from the Karplus equation for a solution conformation similar to the crown shaped conformation in the crystals. The pattern of the C-4 methylene group hydrogens therefore may be used for the assignment of the relative stereochemistry of the various diastereomers of the 8-membered dichlorolactones in a crown conformation.

The dichloroacetate 21 having two methyl substituents at the 3-position of the alkenyl chain gave the eight-membered lactone 47 (75%. entry 6) as an inseparable mixture of the two diastereomers with a *cis:rrms* ratio of 70:30. The trichloroacetate 22 cyclized to the trichlorooxocan-2-one 48 as a single crystalline product (50%, entry 7). In both cases, reaction temperatures of 110-120 'C! were employed to achieve complete conversion in 18 h.

The dichloroacetate 23 cyclized readily at 150 °C in 1 h to a diastereomeric mixture (73:27) of the eightmembered lactone 49 (entry 8). The relative low yield of 52% probably reflects the steric hindrance at the introduction of the chlorine atom on the tertiary C-5 of the product. The major isomer 49^a showed upon irradiation of the C-S methyl substituent a NOE effect on H-3 and on one of the C-4 protons. Assuming a crown conformation, this means that the methyl substituent takes a *pseudo-*axial and the chlorine substituent on C-3 a pseudo-equatorial position, reflecting the cis-diastereomer of 49. The trichloroacetate 24 (entry 9) cyclized at 120 'C to lactone 50 in a 57% yield in which the methyl substituent occupies the pseudo-axial position in a crown shaped ring, as inferred from a **NOE** experiment. The splitting patterns in the 'H NMR of the *cis-* and trans-isomers of lactones 47 and 49 show similar features as described above (see Table 3) for the other lactones.

 (E) -4-Hexenyl dichloroacetate 25 cyclized in a slow process at 120 °C in 20 h to 48% of a mixture of the four possible diastereomers of the eight-membered lactone **51** (entry 10). The major isomer **51a** could be isolated from this mixture by crystallization and was characterized from NOE experiments as pseudo-allequatorial having the chlorine atoms in a relative cis-relationship to each other, and the methyl substituent trans.

Figure 5: Crystal structure of **51a** (Chem $3D^{TM}$ view)

Remarkably the crystal structure of **51a** (Figure 5, Table 5)24 did not show a crown conformation in the solid state, but instead a chairboat arrangement in which C-5 is bent out of the crown leading to an scis-lactone geometry (dihedral angle 4") and an axial C-5 chlorine substituent. The other two substituents on C-3 and C-4 occupy equatorial positions. In solution however, a crown conformation was observed: The vicinal coupling constant for the H-3/H-4 and the H-4/H-5 pairs were both 9.7 Hz, which is expected for a crown conformation where the angles between these two hydrogen pairs are similar. In the

crystal structure, however, these dihedral angles were 179" and 74" respectively. The isomer **51b** could be separated by chromatography and was characterized as an epimer of the first diastereomer at C-3, leading to a relative trans-relationship between the chlorine substituents. The coupling constants of the H-3/H-4 pair is 3.5 Hz, and for the H-4/H-5 pair 8.8 Hz. By NOE experiments on the C-4 methyl subtituent effects were observed on H-3, H-4, and H-5, respectively. In a crown shaped ring the small coupling constant for H-3/H-4 is obtained for a cis-relationship between the chloro and the methyl substituents (small dihedral angle) and the larger coupling constant for H-4/H-5 for a relative *trans*-relationship between the respective substituents (large dihedral angle). The other two inseparable diastereomers possess an eight-membered ring structure as seen from their ¹H NMR data. Of the two possibilities for ring closure only 8-*endo* cyclization took place.

This regioselective ring closure is also found in the cyclization of the corresponding trichloroacetate 26 (entry 11). Only one diastereomer is formed in a yield of 33%, characterized by NOE as the trans-isomer: Irradiation of the methyl group showed an enhancement of H-4 and H-5 (equatorial methyl group in a crown shaped ring). The coupling constant for H-4/H-5 is 10.0 Hz, which corresponds to a *trans*-relationship between H-4 and H-5 (large dihedral angle) and an equatorial C-5 chlorine substituent No seven-membered product was observed in agreement with the results of the cyclization of 25. The latter two cyclizations (entries 10 and 11) proceeded much slower as compared to the terminally unsubstituted alkenes.

The dimethyl substituted alkenyl di- and tichloroacetates 27 and 28 were also treated with Cu(bpy)Cl. In both cases at temperatures between 120 and 170 'C, the starting materials remained unchanged (entries 12 and 13). Terminal alkene substituents thus substantially reduce the cyclization rate and terminal disubstitution apparently renders the ring closure impossible.

The application of the *rigid chain approach*

The failure of the cyclization of the 6-heptenyl di- and trichloroacetates 11 and 12 as well as the loundecenyl dichloroacetate 13 (see Table 1) necessitated the development of a different strategy. The flexibility of the long carbon chain probably favours intermolecular addition over intramolecular reaction via entropy effects. Therefore a rigid element in the carbon chain might suppress such effects.

Table 4: The rigid chain approach

a) 0.3 equiv of Cu(bpy)CI was employed in all cases. b) inseparable mixture.

For this purpose an alkyne functionality was introduced into the alkenyl chain. Dichloroacetate 29 was treated with Cu(bpy)Cl (entry 1, Table 4). However, the starting material remained unchanged at temperatutes between 80 and 160 "C.

At 120 °C the more reactive trichloroacetate 30 (entry 2) cyclized in the endo-mode to a ten-membered system 53 in 36% isolated yield. The desired product was accompanied by various telomers, making purification by flash chromatography laborious. Higher dilution of the reaction mixture (0.03 M, 10 h at 120 "C) did not suppress telomerization, but only 17% of the ten-membered ring could be isolated from an incomplete reaction.

The dichloroacetate 31, having a (Z)-alkene functionality cyclized to the ten-membered lactone 54 (entry 3). In addition, extensive telomerization took place. Only one diastereomer could be isolated from the reaction mixture. Its relative stereochemistry was assigned as *cis,* as could be inferred from the characteristic splitting pattern of H-4ax (dt, $J = 11.9$, 13.8 Hz) in the ¹H NMR. Similar patterns were obtained for the 8- and 9membered lactones (see Table 3). At lower temperatures the starting material remained unchanged.

The trichloroacetate 32 afforded after reflux for 3 days 74% of crude cyclic material but only 37% of the ten-membered lactone 55 after purification. Attempts to cyclize 32 at temperatures between 125 and 140 'C were unsuccessful as only telomers were formed.

Dichloroacetate 33 was treated with 0.3 equiv of Cu(bpy)Cl at various temperatures. Reflux in PhH gave 51% of a mixture of two diastereomers of the eleven-membered lactone 56 in the ratio of 67:33, separated by chromatography. The relative stereochemistry of the two diastereomers could not be established by NMR techniques. Higher reaction temperatures (up to 175 'C) led to a decrease in yield and increasing telomer formation.

The trichloroacetate 34 led to an eleven-membered system 57 at 175 'C, although the yield was poor. Telomerization was the predominant process. At reflux in DCE for 4 days the starting material remained unchanged.

Although the yields of the cyclizations collected in Table 4 are rather low, lO- and 1 l-membered rings are accessible by incorporating a rigid element into the alkenyl chain. For this purpose alkyne and alkene functionalities are suitable. All products formed are the result of *endo-cyclization* of the acetate precursor.

DISCUSSION

The catalyst Cu(bpy)Cl is prepared *in situ* from equimolar amounts of CuCl and the 2.2'-bipyridine ligand. Upon simple mixing of the two components in the reaction vessel containing solvent and reactant, an active catalyst is formed. It is assumed that this catalyst consists of a Cu(I) species which formally abstracts a chlorine atom from the starting material A (see Scheme 3) to furnish a carbon radical B and a Cu(II) species.^{6b} The carbon radical B is stabilized by the captodative effect, which is a characteristic of our previous work and is believed to be crucial for its success.²⁶ This stabilized radical attacks onto the alkene functionality leading to a new unstabilized carbon radical C, which abstracts a chlorine atom from the previously formed Cu(II) complex to give the product D (lactone) and a Cu(I) species which can undergo another catalytic cycle.

Scheme 3. Catalytic cycle $(R = H \text{ or } Cl)$

The combination of equimolar amounts of CuCl and 2,2'-bipyridine in a solvent containing a dichloroacetate leads to the formation of a red-brown solution (probably due to the soluble Cu(bpy)Cl complex), which rapidly turns to a transparent green solution, when the reaction mixture is heated to 80 'C. On cyclization of trichloroacetates, the initial red-brown colour cannot be observed. The reaction mixture turns green immediately at room temperature, due to the higher reactivity of this type of ester. When a solution of the catalyst in DCE is heated without substrate, the solution keeps its red-brown colour. The colour change can be ascribed to the Cu(I) \rightarrow Cu(II) oxidation by chlorine atom abstraction from the starting material. A few minutes after the addition of the catalyst a bright green insoluble material begins to precipitate, but no decrease of catalytic activity can be observed at this stage (the reaction mixture mainly contains starting material). The application of degassed solvents or an argon atmosphere does not prevent the formation of this green solid. Therefore, the formation of the green solid is not caused by O_2 , as reported earlier^{4a} and higher yields can not be achieved by working with carefully degassed solvents.

The use of 0.3 equiv of Cu(bpy)Cl is essential for the success of the cyclization, as lower yields of product are obtained by lowering the amount of catalyst, which may be due to its gradual decomposition. The reaction is preferably carried out in a 0.07 to 0.2 M solution (standard 0.1 M) in order to suppress telomerization processes due to intermolecular additions. At higher concentration more telomers are obtained. More dilute reaction mixtures (up to 0.01 M) show suppression of telomerization, but considerable amounts of starting material remain unchanged and very low yields of products are isolated. In the latter case the *concentration* of catalytically active species is significantly lower and *cyclization is not* complete before total catalyst decomposition has taken place. In general, trichloroacetates tend to be more reactive towards telomerization, expressed in the lower yield of medium-sized lactones isolated compared to the dichloroacetates, and the larger amount of telomers detected.

At temperatures below 80 "C cyclization becomes very slow and incomplete even after several hours of stirring. When the temperature is raised to 180 °C two effects are important: Firstly, the reaction is more rapid, reducing the reaction time from 18 h at 80 'C to about 1 h at temperatures above 160 'C. Secondly, the higher temperature facilitates the reactions of sterically hindered chloroacetates. All starting esters subjected to temperatures of up to 180 °C were thermally stable. Moreover, we did not observe decomposition of lactone 46 when it was treated with the Cu-catalyst under standard conditions at 180 °C.

The endo-mode of the cyclizations is supported by earlier observations and calculations on the radical ring closure to 8-membered carbocycles.²¹ On the other hand we were unable to cyclize τ using genuine free radical conditions. Thus, treatment of 7 with 1.1 equiv of HSnBu₃ and a catalytic amount of AIBN in refluxing PhH^{8a} gave 34% of starting material 7.32% of reduced 7 (monochloroacetate) as well as telomeric material. We could not detect any lactone formation by using this cyclixation technique.

Pyridyl amines and various 2,2'-bipyridines disubstituted at the 4-positions with methoxy, methoxycarbonyl and carboxylic acid groups were unsuccessful as ligands in the cyclization or gave very low yields of product. Without the bipyridine ligand present, no products could be observed in 1,2-dichloroethane.

The formation of C-C bonds catalyzed by the Cu(bpy)Cl system is generally believed to proceed through free or metal coordinated²⁷ radicals, called 'radical-pairs', in which a radical interacts strongly with the metal centre. Thus the incipient radical can be bonded to the $Cu(II)$ which is formed after formal oxidation of the catalyst by chlorine atom abstraction.

Assuming radical-pairs the substrate is bonded intimately to the catalyst and therefore carbon-carbon bond formation takes place very close to or within the co-ordination sphere of the metal complex causing the carbon chain to fold in accord with the geometry of the complex. The following observations support this proposal of a template effect:

1) the extremely selective *endo-mode* cyclization of the various alkenyl acetates. In this series the exclusive endo-cyclizations of 25 and 26 are remarkable.

2) the inability to achieve g-membered ring formation of dichloroacetate 7 applying reductive radical cyclization with HSnBug.

3) the slower reaction rate in the cyclizations of substituted alkyl chains, which results in higher temperatures necessary for lactone formation. The failure to cyclize the 1,1-disubstituted precursor 18 even at high temperatures is remarkable. The substituents probably interact sterically with the Cu-complex. This interaction becomes larger when the substituents are located closer to the ester function.

4) best results are obtained for 8- and 9-membered lactones. The synthesis of lO- and 1 l-membered rings is possible by the introduction of a rigid element into the alkenyl chain, presumingly due to a better fit in the catalyst complex by decreasing the flexibility of the chain.

In conclusion, the Cu(I) mediated cyclization of substituted alkenyl di- and trichloroacetates is a versatile tool for the construction of 8- to 11- membered lactone systems. The cyclization is regioselective for *endo*-ring closure and the products obtained are often fonned in good yields.

ACKNOWLEDGEMENTS

W. J. M. Steeman is gratefully acknowledged for his contribution to the synthetic part of this project. J. Fraanje and K. Goubitz (Laboratory of Crystallography, University of Amsterdam) are kindly acknowledged for the X-ray crystal structure determinations.

EXPERIMENTAL

General information. All reactions were carried out under an inert atmosphere of dry nitrogen. Standard syringe techniques were applied to transfer dry solvents. Infrared (IR) spectra were obtained from CHCl3 solutions using a Perkin-Elmer 1310 spectrophotometer and wavelengths (v) are reported in cm⁻¹. Proton nuclear resonance $(^1H NMR)$ spectra were determined in CDC13. unless indicated otherwise using a Bruker AC 200 (200 MHZ), a Bruker WM 250 (250 MHx), a Bruker AMX 300 (300 MHz) or a Bruker AMX 400 (400 MHz) spectrometer. These instruments were also used for ¹³C NMR (APT) spectra (50, 63, 75.5 and 100.6 MHz respectively) **in** CDCl3 (unless indicated otherwise). Chemical shifts (8) are given in ppm downfield from tetramethylsilane. Mass spectra and accurate mass measurements were canied out using a Jeol SX/SX 102 A Tandem Mass Spectrometer, a Varian MAT 7 11 or a VG Micromass ZAB-2HP instrument. Elemental analysis were performed by Bornis u. Kolbe Mikroanalytisches Laboratorium, Mulheim an der Ruhr, Germany. Rf values were obtained by using thin-layer chromatography (TLC) on silica gel-coated plastic sheets (Merck silica gel 60 F254) with the indicated solvent mixture of ethyl acetate and hexanes of the given ratio (EtOAc:hexanes). Chromatographic purification refers to flash chromatography²⁸ (fc) using a solvent mixture of ethyl acetate and hexanes in the given ratio and Janssen Chhnica silica gel (0.030-0.075 mm). Melting points are uncorrected. CH₂Cl₂ and (CH₂Cl₎₂ were distilled from P₂O₅ and stored over MS 3Å under an atmosphere of dry nitrogen. Benzene was distilled from P2O5 and stored over sodium-wire. Dry THF and Et2O were distilled from sodium benzophenone ketyl prior to use. CuCl was purified.²⁹ Reactions 'in sealed tubes' were carried out in thick-walled glass tubes (3 to 15 cm long and 0.5 to 4 cm wide) equipped a thread, which could be screwed tight with a plastic cap.

General procedure A for the esterification of alkenols to di- and trichloroacetates:¹⁰ A solution of di- or trichloroacetyl chloride (usually 1.0-1.3 equiv) in a 0.3 M solution of CH₂Cl₂ was cooled in an ice bath. The alkenol (1 equiv) was added in one portion, followed by dropwise addition of Et3N (2 equiv) as a 3 M solution in CH₂Cl₂ over 20 minutes. The r.m. was stirred for 1 h at 0 °C and then poured into an equal volume of 2 M HCl(aq). The organic phase was separated, and the aqueous phase was extracted with 3 portions of CH₂Cl₂. The combined organic phases were dried on MgSO₄ or Na₂SO₄, concentrated in vacuo and the residue was purified by fc.

General procedure B for the Cu-catalyzed cyclization of di- and trichloroacetates to medium-sized **lactones:** The di- or trichloroacetate was dissolved in 1,2-dichloroethane or benzene (0.1 M solution) in a flask under a N₂ atmosphere. Catalytic amounts of CuCl (0.3 equiv) and of 2,2-bipyridine (0.3 equiv) were added simultaneously, and the mixture was immediately heated to teflux (80 'C). When the reaction was carried out at temperatures between 80 and 190 'C a seatable tube was used, charged with acetate and solvent, equipped with a stirring bar, placed under a N₂ atmosphere, and closed after addition of the two ingredients of the catalyst. It was immersed into an oil bath preheated at the desired tempemture and stirred for several hours. When the conversion was complete (TLC-check, the tube was cooled in a water bath to r.t. prior to opening and rinsed with N_2 before closing the tube to continue the reaction), the reaction mixture was concentrated *in vacuo* and the green residue was directly purified by flash chromatography without further workup. The lactone products were sensitive to humidity and were therefore kept under a N2 atmosphere.

Dichloroacetic acid but-3-enyl ester (5)³⁰: According to the general procedure A, a solution of dichloroacetyl chloride (1.0 g, 6.7 mmol, 1.0 equiv) and 3-buten-1-ol (483 mg, 6.7 mmol) in 20 mL of CH2Cl2 was treated with Et3N (1.36 g, 13.4 mmol, 2 equiv) in 5 mL of CH2Cl2. The r.m. was stirred at 0 °C for 1 h. Work-up and fc (1:10) afforded 5 (1.20 g, 6.6 mmol, 98%) as a colourless oil. $R_f(1:8)$ 0.80; IR v 3180, 3000, 2980, 1760, 1740, 1635, 1460; ¹H NMR (200 MHz) δ 2.47 (dq, 2 H, J = 1.3, 6.7 Hz, 2 H-2). 4.32 (t, 2 H, J = 6.7 Hz, 2 H-l), 5.05-5.20 (m, 2 H, 2 H-4), 5.70-5.90 (m, 1 H, H-3), 5.94 (s, 1 H, $CHCl₂$).

Trichloroacetic acid but-3.enyl ester (6) 30: According to the general procedure A, a solution of trichloroacetyl chloride (689 mg, 3.79 mmol, 1.1 equiv) and 3-buten-1-ol (248 mg, 3.44 mmol) in 10 mL of CH₂Cl₂ was treated with Et₃N (694 mg, 6.88 mmol, 2 equiv) in 2 mL of CH2Cl2. The r.m. was stirred at 0 'C for 1 h. Work-up and fc (1:lO) afforded 6 (650 mg, 2.99 mmol, 87%) as a colourless oil. Rf (1:10) 0.90; IR v 3080, 2960, 1760, 1635, 1445, 1375, 1240, 1015, 980, 915, 865, 825;

lH NMR (200 MHz) 6 2.52 (q. 2 H, J = 6.7 Hz, 2 H-2). 4.41 (t. 2 H, J = 6.7 Hz, 2 H-l), 5.10-5.25 (m, 2 H. 2 H-4). 5.81 (ddt, 1 $H, J = 6.7, 10.3, 17.1$ Hz, H-3).

Dichloroacetic acid pent-4-enyl ester $(7)^{30}$ **:** According to the general procedure A, a solution of dichloroacetyl chloride (1.0 g, 6.7 mmol, 1.0 equiv) and 4-penten-1-ol (577 mg, 6.7 mmol) in 20 mL of CH₂Cl₂ was treated with Et₃N (1.36 g, 13.4 mmol, 2 equiv) in 5 mL of CH₂Cl₂. The r.m. was stirred at 0 °C for 1 h. Work-up and fc (1:10) afforded 7 (1.32 g, 6.7 mmol, 100%) as a colourless oil. R_f (1:4) 0.80; IR v 3180, 3020, 2960, 2940, 2840, 1760, 1740, 1635, 1460, 1445; ¹H NMR (200 MHz) 6 1.82 (quintet, 2 H, J = 6.7 Hz, 2 H-2). 2.10-2.25 (m, 2 H, 2 H-3). 4.28 (f 2 H. J = 6.5 Hz, 2 H-l), 4.95-5.10 (m. 2 H, 2 H-5), 5.70-5.90 (m, 1 H, H-4), 5.94 (s, 1 H, CHCl2); ¹³C NMR (50 MHz) δ 27.1 (CH2), 29.3 (CH2), 64.1 (CHCl2), 66.5 (C-l), 115.4 (C-5). 136.6 (C-4). 164.1 (CO).

Trichloroacetic acid pent-4-enyl ester (8)³⁰: According to the general procedure A, a solution of trichloroacetyl chloride (6.3 g, 34.8 mmol, 1.0 equiv) and 4-penten-1-ol (3.0 g, 34.8 mmol) in 100 mL of CH2Cl2 was treated with Et3N (7.03 g, 69.6 mmol, 2 equiv) in 25 mL of CH2Ci2. The reaction was stirred for 3 h at rt. Work-up and fc (1:20) afforded 8 (8.06 g. 34.8 mmol, 100%) as a colourless oil. $R_f(1:6)$ 0.95; IR v 3070, 2940, 2840, 1760, 1630, 1460, 1440, 1250, 970, 820; ¹H NMR (200 MHz) δ 1.88 (quintet, 2 H, J = 6.6 Hz, 2 H-2), 2.19 (q, 2 H, J = 7.3 Hz, 2 H-3), 4.38 (t, 2 H, J = 6.5 Hz, 2 H-1), 5.00-5.15 (m, 2 H, 2 H-5), 5.81 (ddt, 1 H, J = 6.6, 10.3, 17.0 Hz, H-4); ¹³C NMR (50 MHz) δ 27.1 (CH₂), 29.4 (CH₂), 68.3 (C-1), 89.8 (CCl3). 115.8 (C-5). 136.4 (C-4). 161.5 (CO).

Dichloroacetic acid hex-5-enyl ester (9): According to the general procedure A, a solution of dichloroacetyl chloride $(1.0 \text{ g}, 6.7 \text{ mmol}, 1.0 \text{ equiv})$ and 5-hexen-1-ol $(671 \text{ mg}, 6.7 \text{ mmol})$ in 20 mL of CH₂C1₂ was treated with Et₃N $(1.36 \text{ g}, 13.4 \text{ m})$ mmol, 2 equiv) in 5 mL of CH₂Cl₂. The reaction was stirred 1 h at 0 °C. Work-up and fc (1:10) afforded 9 (1.20 g, 5.7 mmol, 85%) as a colourless oil. $R_f(1:8)$ 0.65; IR v 3080, 3020, 2940, 2860, 1760, 1740, 1635, 1465, 1455, 1435, 1386; ¹H NMR (200 MHz) 6 1.40-1.50 (m, 2 H, 2 H-3). 1.60-1.80 (m. 2 H, 2 H-2). 2.00-2.15 (m, 2 H, 2 H-4). 4.26 (t, 2 H, J = 6.5 Hz, 2 H-l), 4.90- 5.05 (m, 2 H, 2 H-6), 5.65-5.85 (m, 1 H, H-5), 5.93 (s, 1 H, CHCl2); ¹³C NMR (50 MHz) δ 24.8 (CH₂), 27.7 (CH₂), 33.1 (CH2). 64.3 (CHCl2). 67.5 (C-l), 115.1 (C-6). 138.0 (C-5). 164.1 (CO).

Trichloroacetic acid hex-5enyl ester (10): According to the general procedure A, a solution of trichloroacetyl chloride (798 mg, 4.39 mmol, 1.1 equiv) and 5-hexen-1-ol (400 mg, 3.99 mmol) in 12 mL of CH2Cl2 was treated with Et3N (806 mg. 7.98 mmol, 2 equiv) in 3 mL of CH2Cl2. The reaction was stirred for 1 h at 0 'C. Work-up and fc (1:lO) afforded **10** (848 mg, 3.45 mmol, 86%) as a colourless oil. R_f (1:10) 0.75; IR v 3080, 2940, 2860, 1760, 1635, 1245, 990, 910, 825; ¹H NMR (200 MHz) 6 1.45-1.60 (m, 2 H, 2 H-3), 1.70-1.90 (m, 2 H, 2 H-2). 2.05-2.20 (m, 2 H, 2 H-4). 4.37 (I, 2 H, J = 6.4 Hz, 2 H-l), 4.90- 5.10 (m, 2 H, 2 H-5), 5.79 (ddt, 1 H, J = 6.6, 10.2, 17.0 Hz, H-4); ¹³C NMR (50 MHz) δ 24.6 (CH₂), 27.4 (CH₂), 32.8 (CH₂), 69.0 (C-l), 89.8 (CCl3). 115.0 (C-6), 137.6 (C-5). 161.5 (CO).

Dichloroacetic acid hept-6-enyl ester (11): To a suspension of 455 mg of LiAlH4 (12 mmol, 8 equiv) in 5 mL of dry Et2O was added dropwise of 6-heptenoic acid (200 mg, 1.5 mmol) in 15 mL of Et2O at r.t. The r.m. was refluxed for 6 h and quenched by addition of 2 mL of MeOH, followed by 30 mL of 5% H₂SO₄ and extraction of the aqueous layer with 4 portions of 20 mL of Et20. The combined organic phases were dried on MgSO4 and concentrated *in WCIW. The* crude product was essentially pure 6-hepten-l-01 (171 mg, 100%). According to the general procedure A, a solution of dichloroacetyl chloride (221 mg, 1.5 mmol, 1.0 equiv) and 6-hepten-1-ol (190 mg, 1.5 mmol) in 5 mL of CH₂Cl₂ was treated with Et₃N (303 mg, 3.0 mmol, 2 equiv) in 1 mL of CH2Cl2. The reaction was stirred 1 h at 0 'C. Work-up and fc (1:6) **afforded 11 (316 mg, 1.4 mmol, 94%) as a** colourless oil. $R_f(1:6)$ 0.90; ¹H NMR (200 MHz) δ 1.35-1.55 (m, 4 H, 2 CH₂), 1.65-1.85 (m, 2 H, CH₂), 2.00-2.15 (m, 2 H, 2 H-5), 4.27 (t. 2 H, J = 6.6 Hz, 2 H-1), 4.90-5.07 (m, 2 H, 2 H-7), 5.65-5.85 (m, 1 H, H-6), 5.94 (s, 1 H, CHCl2); ¹³C NMR (50 MHz) 6 25.0 (CH2). 28.1 (CH2). 28.3 (CH2). 33.5 (CH2). 64.3 (CHCl2). 67.6 (C-l), 114.6 (C-7). 138.4 (C-6). 164.4 (CO).

Trichloroacetic acid bept-6-enyl ester (12): According to the general procedure A, a solution of trichloroacetyl chloride (627 mg, 3.54 mmol, 1.1 equiv) and 6-hepten-1-ol (368 mg, 3.23 mmol) in 10 mL of CH₂Cl₂ was treated with Et3N $(651 \text{ mg}, 6.45 \text{ mmol}, 2 \text{ equity})$ in 2 mL of CH₂Cl₂. The reaction was stirred for 1 h at 0 °C and 18 h at rt. Work-up and fc $(1:20)$ afforded 12 (556 mg, 2.14 mmol, 66%) as a colourless oil. $R_f(1:10)$ 0.60; IR v 3010, 2970, 2930, 2850, 1760, 1630, 1220; ¹H NMR (200 MHz) 6 1.35-1.50 (m, 4 H, 2 CH2), 1.70-1.90 (m, 2 H, CH2), 2.00-2.15 (m. 2 **H,** 2 H-5). 4.36 (t, 2 H, J = 6.6 Hz, 2 H-1), 4.90-5.07 (m, 2 H, 2 H-7), 5.79 (ddt, 1 H, J = 6.9, 10.2, 17.0 Hz, H-6); ¹³C NMR (50 MHz) δ 24.8 (CH2), 27.9 (CH2), 28.1 (CH₂), 33.3 (CH₂), 69.3 (C-1), 89.9 (CCl₃), 114.6 (C-7), 138.2 (C-6), 161.8 (CO).

Dichloroacetic acid undec-10-enyl ester (13): According to the general procedure A, a solution of dichloroacetyl chloride (1.0 g, 6.7 mmol, 1.0 equiv) and 10-undecen-1-ol (1.14 g, 6.7 mmol) in 20 mL of CH₂Cl₂ was treated with Et₃N (1.36 g, 13.4 **mmol, 2 equiv)** in 5 mL of CH2C12. The reaction was stirred 1 h at 0 'C. Work-up and fc (1:lO) afforded 13 (1.60 g. 5.7 mmol, 85%) as a colourless oil. Rf (1:10) 0.70; IR v 3070, 2920, 2850, 1760, 1740, 1635, 1460; ¹H NMR (250 MHz) δ 1.20-1.45 (m, 12 H, 6 CH2). 1.62-1.78 (m. 2 H. CH2). 1.95-2.08 **(m,** 2 H, 2 H-9). 4.25 (t. 2 H, J = 6.7 Hz, 2 H-l), 4.85-5.00 (m. 2 H, 2 H-11), 5.70-5.90 (m, 1 H, H-10), 5.92 (s, 1 H, CHCl₂); ¹³C NMR (50 MHz) δ 25.3 (CH₂), 28.0 (2 CH₂), 28.6 (CH₂), 28.8 (2 CH2). 29.1 (CH2). 33.5 (CH2). 64.1 (CHCl2), 67.2 (C-l), 113.9 (C-11). 138.6 (C-10). 164.1 (CO).

Dicbloroacetic acid pent4-ynyl ester (14): According to the general procedure A, a solution of dichloroacetyl chloride (483 mg, 3.3 mmol, 1.0 equiv) and 4-pentyn-1-ol (276 mg, 3.3 mmol) in 10 mL of CH₂Cl₂ was treated with Et3N (668 mg, 6.6 mmol, 2 equiv) in 2 mL of CH2C12. The reaction was stirred for 1 h at 0 'C. Work-up and fc (1:4) afforded 14 (562 mg, 2.9 mmol, 87%) as a light yellow oil. *Rf* (1:3) 0.60, IR v 3300, 2960, 2930, 2840, 2110, 1760, 1740, 1460, 1440. 1430, 1385, 1370, 810; ¹H NMR (200 MHz) δ 1.85-2.05 (m, 3 H, 2 H-2, H-5), 2.34 (dt, 2 H, J = 2.6, 7.0 Hz, 2 H-3), 4.40 (t, 2 H, J = 6.2 Hz, 2 H-1), 5.95 (s, 1 H, CHCl₂); ¹³C NMR (50 MHz) δ 14.7 (C-3), 26.9 (C-2), 64.1 (CHCl₂), 65.7 (C-1), 69.3 (C-4), 82.2 (C-5). 164.2 (CO).

Trichloroacetic acid pent-4-ynyl ester (15): According to the general procedure A, a solution of trichloroacetyl chloride (1.43 g, 7.8 mmol, 1.1 equiv) and 4-pentyn-1-ol (600 mg, 7.13 mmol) in 24 mL of CH2Cl2 was treated with Et3N (1.44 g, 14.3 mmol, 2 equiv) in 8 mL of CH2Cl2. The reaction was stirred for 1.5 h at 0 'C. Work-up and fc (1:8) afforded 15 (1.51 g, 6.56 mmol, 92%) as a colourless oil. *R_f*(1:8) 0.65; IR v 3300, 3030, 2960, 2840, 1760, 1460, 1440, 1430, 1245, 1020, 820; ¹H NMR (200 MHz) δ 1.90-2.07 (m, 3 H, 2 H-2 and H-5), 2.37 (dt, 2 H, J = 2.6, 6.9 Hz, 2 H-3), 4.49 (t, 2 H, J = 6.1 Hz, 2 H-1); 13 C NMR (50 MHz) δ 14.8 (C-3), 26.9 (C-2), 67.5 (C-1), 69.6 (C-4), 82.0 (C-5), 89.7 (CC13), 161.7 (CO).

Dichloroacetic acid I-methyl-pent-4-enyl ester (16): A suspension of 531 mg of magnesium chips (22.1 mmol, 1.1 equiv) in 3 mL of dry Et₂O was treated with of 5-bromo-1-pentene (3.0 g, 20.1 mmol) in 30 mL of Et₂O and the resulting Grignard reagent was refluxed for 1 h. At 10 °C a solution of 10.9 g of acetaldehyde (0.25 mol, 12 equiv) in 10 mL of Et₂O was added dropwise over 30 minutes, the reaction mixture was stirred for 2 h at rt and pouted into ice/15% H2SO4. The aqueous layer was extracted with Et₂O (3 x 50 mL), the combined organic phases were dried (MgSO₄), concentrated *in vacuo* and purified by fc (1:5). This yielded 913 mg (10.8 mmol, 54%) of 5-hexen-2-01. **According to the** general procedure A, a solution of dichloroa&yl chloride $(1.09 \text{ g}, 7.15 \text{ mmol}, 1.0 \text{ equiv})$ and 5-hexen-2-ol $(602 \text{ mg}, 7.15 \text{ mmol})$ in 20 mL of CH₂Cl₂ was treated with Et3N (1.44 m) g, 14.3 mmol, 2 equiv) in 4 mL of CH₂Cl₂. The reaction was stirred for 18 h at r.t.. Work-up and fc (1:3) afforded 16 (1.27 g, 6.0 mmol, 84%) as a colourless oil. *R_f* (1:3) 0.75; IR v 3080, 2980, 2940, 2850, 2240, 1750, 1670, 1390, 1380, 1170, 900; ¹H NMR (200 MHz) δ 1.33 (d, 3 H, J = 6.2 Hz, CH3), 1.57-1.90 (m, 4 H, 2 H-3 and 2 H-4), 2.20 (sextet, 1 H, J = 6.5 Hz, H-2), 4.95-5.05 (m, 2 H, 2 H-6), 5.75 (ddt, 1 H, $J = 6.6$, 10.1, 17.0 Hz, H-5), 5.92 (s, 1 H, CHCl₂).

Dichloroacetic acid I-phenyl-pent-4-enyl ester (17): A suspension of 396 mg of magnesium chips (16.3 mmol, 1.1 equiv) in 5 mL Et20 was treated with a solution of of 4-bromo-1-butene (2.0 g, 14.8 mmol) in 50 mL of Et20. The resuhing Grignard reagent was refluxed for 1 h, then cooled down to -10 °C, followed by the slowly addition of benzaldehyde (1.65 g, 1.05 equiv, 15.5 mmol) keeping the temperature below -5 'C. The r.m. was slowly brought to r.t. and poured into 100 g of ice and 15 mL of H₂SO₄. 1-Phenyl-4-penten-1-ol¹¹ was obtained by extraction with Et₂O (3 x 50 mL), drying on Na₂SO₄, concentration in vacuo and purification by fc (1:3.5) as a colourless oil (1.49 g, 9.18 mmol, 62%). *Rf* (1:3.5) 0.40, IR v 3600, 3440, 3070, 3000, 2930, 2850, 1630, 1490, 1445, 910; ¹H NMR (200 MHz) δ 1.63 (bs, 1 H, OH), 1.70-2.00 (m, 2 H, 2 H-2), 2.00-2.25 (m, 2 H, 2 H-3), 4.70 (dd, 1 H, J = 5.9, 7.3 Hz, H-1), 4.95-5.12 (m, 2 H, 2 H-5), 5.75-5.95 (m, 1 H, H-4), 7.20-7.40 (m, 5 H, Ar). According to the general procedure A, a solution of dichloroacetyl chloride (770 mg, 5.2 **mmol,** 1.2 equiv) and I-phenyl-4-penten-l-ol(705 mg, 4.3 mmol) in 15 mL of CH2Cl2 was treated with Et3N (870 mg, 8.6 mmol, 2 equiv) in 5 mL of CH2Cl2. The reaction was stirred for 2 h at 0 °C. Work-up and fc (1:8) afforded 17 (745 mg, 2.7 mmol, 63%) as a colourless oil. From the r.m. 280 mg of starting alcohol was isolated, corrected for starting material the yield of esterification was 100% . $R_f(1:8)$ 0.75; IR v 3060, 3000, 2940, 1755, 1630, 1490, 1445, 910, 790; ¹H NMR (200 MHz) δ 1.90-2.25 (m, 4 H, 2 H-2 and 2 H-3), 4.95-5.15 (m, 2 H, 2 H-5). 5.70-5.95 (m. 2 H, H-l and H-4). 5.95 (s, 1 H, CHC12). 7.25-7.45 (m, 5 H, Ar); 13C NMR (50 MHZ) 6 29.4 (C-3), 35.0 (C-2). 64.4 (CHCl2). 78.9 (C-l), 115.7 (C-5). 126.3, 126.3, 128.4, 128.5, 128.5, 136.7 (C-4). 138.7, 163.5 (CO).

Dicbloroacetic acid 1,1-dimethyl-pent-4.enyl ester (18): According to the preparation of 17, 396 mg of magnesium chips (16.3 mmol, 1.1 equiv) in 5 mL of Et₂O were treated with of 4-bromo-1-butene (2.0 g, 14.8 mmol) in 15 mL of Et2O. followed by 30 minutes of reflux. At r.t. 1.72 g of dry acetone (29.6 mmol. 2 equiv, 2.2 mL) in 10 mL of Et20 was added slowly to the r.m. and stirred for 5 h. After work-up 2-methyl-5-hexen-2-ol¹² (974 mg, 8.53 mmol, 52%) was obtained by fc (1:4) as a light yellow oil. According to the general procedure A, a solution of dichloroacetyl chloride (940 mg, 6.4 mmol, 1.0 equiv) and 2-methyl-5-hexen-2-ol (731 mg, 6.4 **mmol)** in 20 mL of CH2C12 was treated with Et3N (1.3 g. 12.8 mmol, 2 equiv) in 5 mL of CH₂C1₂. The reaction was stirred for 1 h at 0 °C. Work-up and fc (1:6) afforded 18 (727 mg, 3.2 mmol, 50%) as a colourless oil. From the r.m. 345 mg of starting alcohol was isolated, the corrected yield for starting material was 95%. $R_f(1:6)$ 0.90; IR v 3170, 2980, 2920, 2850, 1800, 1750, 1635, 1450, 1380, 1365, 910; ¹H NMR (200 MHz) δ 1.52 (s, 6 H, 2 CH3), 1.85-2.00 (m, 2 H, 2 H-2), 2.10-2.25 (m, 2 H, 2 H-3), 4.95-5.10 (m, 2 H, 2 H-5), 5.70-5.95 (m, 1 H, H-4), 5.83 (s, 1 H, CHCl2); ¹³C NMR (50 MHz) 6 25.3 (2 CH3), 27.8 (C-3). 39.5 (C-2). 65.1 (CHCl2). 86.7 (C-l), 114.7 (C-5). 137.6 (C-4). 163.2 (CO).

Dichloroacetic acid 2,2-dimethyl-pent-4.enyl ester (19): According to the **preparation** of 11, 3.87 g of 2,2 dimethyl-4-penten-1-al (34.5 mmol) in 77 mL of Et₂O was treated with of LiAlH₄ (1.96 g, 51.8 mmol, 1.5 equiv). The r.m. was refluxed for 2 h and stirred overnight at r.t. Excess LiAlH4 was treated with 5 mL of MeOH, 200 mL of 5% H2SO4 was added to the mixture and extracted by Et₂O (3 x 100 mL), the organic phases were dried (MgSO₄) and concentrated in vacuo. 2.2-Dimethyl-**4-penten-l-ol13 was** obtained essentially pure (3.53 g, 30.9 mmol, 90%). According to the general procedure A, a solution of dichloroacetyl chloride (567 mg, 3.85 mmol, 1.1 equiv) and 2,2-dimethyl-4-penten-1-ol (400 mg, 3.51 mmol) in 10 mL of CH2Cl2 was treated with Et3N (709 mg, 7.0 mmol, 2 equiv) in 2 mL of CH2Cl2. The reaction was stirred for 10 minutes at 0 °C. Work-up and fc (120) afforded 19 (790 mg, 3.51 mmol, 100%) as a tight yellow oil. *Rf* (1:8) 0.65; IR v 3070, 2960, 1760, 1740, 1640, 1300, 1160, 990,910, 810; lH NMR (200 MHz) 6 0.96 (s, 6 H, 2 CH3). 2.09 (d, 2 H, J = 7.5 Hz, 2 H-3). 3.99 (s, 2 H, 2 H-l), 5.01 (m, 2 H, 2 H-5). 5.85 (m, 1 H, H-4) 5.97 (s, 1 H. CHC12).

Dichloroacetic acid 2.2.dimethyl-pent-4-enyl ester (20): According to the general procedure A, a solution of trichloroacetyl chloride (5.76 g, 31.5 **mmol,** 1.2 equiv) and 2,2dimethyl-4-penten-l-o1 (3.0 g. 26.3 mmol) in 90 mL of CH2C12 was treated with Et3N (5.3 g, 52.6 mmol, 2 equiv) in 7 mL of CH₂Cl₂. The reaction was stirred for 1.5 h at 0 °C. Work-up and fc (1:lO) afforded 20 (6.78 g, 26.1 mmol, 99%) as a colourless oil. Rf(l:lO) 0.90: IR v 3070,296O. 1760, 1635, 1460, 1390, 1365, 1250, 990, 835, 820; lH NMR (300 MHz) 6 0.99 (s, 6 H, 2 CH3). 2.10 (d, 2 H, J = 7.5 Hz, 2 H-3). 4.06 (s, 2 H, 2 H-l), 5.03. 5.15 (m, 2 H, 2 H-5), 5.80 (ddt, 1 H, J = 7.6, 10.3, 16.8 Hz, H-4); ¹³C NMR (50 MHz) δ 23.9 (2 CH₃), 34.6 (CH₂), 43.1 (CH2). 76.3 (C-l), 90.0 (CCl3). 118.3 (C-5), 133.6 (C-4). 161.8 (CO).

Dicbloroacetic acid 3,3-dimethyl-pent-4.enyl ester (21): According to the general procedure A, a solution of dichloroacetyl chloride (1.26 g, 8.6 mmol, 1.1 equiv) and 3,3-dimethyl-4-penten-l-ol¹⁴ (700 mg, 7.8 mmol) in 26 mL of CH₂Cl₂ was treated with Et3N (1.58 g, 15.6 mmol, 2 equiv) in 5 mL of CH₂Cl₂. The reaction was stirred for 2 h at 0 °C. Work-up and fc (1:10) afforded 21 (1.52 g, 6.7 mmol, 87%) as a light yellow oil. R_f (1:10) 0.55; IR v 3080, 2960, 2920, 2860, 1760, 1630, 1460, 1410, 1380, 1360, 1300, 1160, 1000, 970, 915, 810; ¹H NMR (400 MHz) δ 1.06 (s, 6 H, 2 CH₃), 1.73 (t, 2 H, J = 7.3 Hz, 2 H-2), 4.26 (t, 2 H, J = 7.3 Hz, 2 H-1), 4.96 (dd, 1 H, J = 1.0, 17.3 Hz, H-5 trans), 4.98 (dd, 1 H, J = 1.0, 10.3 Hz, H-5 *cis*), 5.77 (dd, 1 H, $J = 11.0$, 17.2 Hz, H-4), 5.91 (s, 1 H, CHCl₂).

Tricbloroacetic acid 3,3-dimethyl-pent-4-enyl ester (22): According to the general procedure A, a solution of trichloroacetyl chloride (1.56 g, 8.6 mmol, 1.1 equiv) and 3,3-dimethyl-4-penten-1-ol¹⁴ (700 mg, 7.8 mmol) in 26 mL of CH₂Cl₂ was treated with Et3N (1.58 g, 15.6 mmol, 2 equiv) in 5 mL of CH2Cl2. The reaction was stirred for 2 h at 0 °C. Work-up and fc **(1:lO) afforded 22 (1.71 g, 6.6 mmol, 85%) as a** colourless oil. Rf(l:lO) 0.75: IR v 3080,2960,2920,2860, 1760, 1635, 1455, 1410,138O. **1360, 1240, 1000,980,915,820,680; lH NMR (400 MHz) 6 1.08 (s, 6 H, 2 CH3). 1.79 (t. 2 H. J = 7.2 Hz, 2** H-2). 4.34 (t, **2 H, J =** 7.2 Hz, 2 H-l), 4.98 (d, 1 H, J = 17.4 Hz. H-5 rrans), 4.99 (d. 1 H, J = 10.7 Hz, H-5 cis). 5.78 (dd, 1 H, J = 11.1, 17.1 Hz, H-4); ¹³C NMR (50 MHz) δ 26.9 (2 CH₃), 35.6 (CH₂), 39.8 (CH₂), 67.1 (C-1), 89.9 (CCl₃), 111.7 (C-5), 146.5 (C-4). 161.9 (CO).

Dichloroacetic acid 4-methyl-pent-4-enyl ester (23): According to the general procedure A, a solution of dichloroacetyl chloride (224 mg, 1.53 mmol, 1.1 equiv) and 4-methyl-4-penten-1-ol¹⁵ (139 mg, 1.39 mmol) in 5 mL of CH₂Cl₂ was treated with Et3N (281 mg, 2.78 mmol, 2 equiv) in 1 mL of CH2Cl2. The reaction was stirred for 1 h at 0 °C. Work-up and fc (1:lO) afforded 23 (255 mg, 1.21 mmol, 87%) as a colourless oil. *Rf* (1:lO) 0.55; lR v 3060, 2960, 2930, 2840, 1760. 1640, 1440, 1370. 1300, 1160, 1035,980, 890,810: lH NMR (400 MHZ) 6 1.73 (s, 3 H, CH3). 1.86 (quintet, 2 H, *J =* 6.9 Ha, 2 H-2). 2.12 (t, 2 H, *J =* 7.7 Hz, 2 H-3). 4.28 (t. 2 H, *J =* 6.6 Hz, 2 H-l), 4.71 (s, 1 H, H-5), 4.76 (s, 1 H, H-5'). 5.94 (s, 1 H, CHC12).

Trichloroacetic acid 4-methyl-pent-4.cay1 ester (24): According to the general procedure A, a solution of trichloroacetyl chloride (356 mg, 1.97 mmol, 1.1 equiv) and 4-methyl-4-penten-1-ol¹⁵ (180 mg, 1.79 mmol) in 5 mL of CH₂Cl₂ was treated with Et3N (362 mg, 3.59 mmol, 2 equiv) in 1 mL of CH2Cl2. The reaction was stirred for 1 h at 0 °C. Work-up and fc (1:20) afforded 24 (405 mg, 1.65 mmol, 92%) as a colourless oil. *Rf* (1:lO) 0.60; IR v 3070, 2920, 2840. 1760, 1640, 1460, 1440, 1370, 1245, 980, 820, 675; ¹H NMR (200 MHz) δ 1.74 (s, 3 H, CH3), 1.92 (quintet, 2 H, *J* = 6.5 Hz, 2 H-2), 2.16 (t, 2 H, *J* = 7.0 Hz, 2 H-3), 4.37 (t, 2 H, *J* = 6.5 Hz, 2 H-1), 4.73 (s, 1 H, H-5), 4.78 (s, 1 H, H-5'); ¹³C NMR (50 MHz) δ 22.0 (CH3), 25.9 (CH2). 33.3 (CH2). 68.6 (C-l), 89.8 (CCl3). 111.0 (C-5), 143.5 (C-4). 161.6 (CO).

(R)-Dichloruacetic acid hex-4-enyi **ester** (25): According to the general procedure A, a solution of dichloroacetyl chloride $(1.13 \text{ g}, 7.69 \text{ mmol}, 1.1 \text{ equiv})$ and (E) -4-hexen-1-ol (700 mg, 6.99 mmol) in 20 mL of CH₂Cl₂ was treated with Et₃N (1.41 g, 14.0 mmol, 2 equiv) in 5 mL of CH2C12. The reaction was stirred for 2 h at 0 'C. Work-up and fc (1:6) afforded 25 (1.39 g, 6.59 mmol, 94%) as a colourless oil. $R_f(1:8)$ 0.55; IR v 3010, 2960, 2940, 2920, 2850, 1760, 1460, 1445, 1435, 1385, 1375, 1250, 1165, 960, 810; ¹H NMR (300 MHz) δ 1.65 (dd, 3 H, $J = 0.8$, 5.8 Hz, CH3), 1.77 (quintet, 2 H, $J = 6.7$ Hz, 2 H-2), 2.09 (q, 2 H, *J =* 6.8 Hz, 2 H-3) 4.27 (t. 2 H, *J =* 6.6 Hz. 2 H-l), 5.35-5.52 (m, 2 H, H-4 and H-5). 5.94 (s, 1 H, CHCl2); 13C NMg (50 MHz) 6 17.7 (C-6). 27.8 (CH2). 28.3 (CH2), 64.2 (CHCI2). 66.9 (C-l), 126.1 (CH=). 129.2 (CH=), 164.4 (CO).

(II)-Tricbloroacetic acid hex4-enyl ester (26): According to the general procedure A. a solution of trichloroacetyl chloride (1.40 g, 7.69 mmol, 1.1 equiv) and (E) -4-hexen-1-ol (700 mg, 76.99 mmol) in 20 mL of CH₂Cl₂ was treated with Et3N (1.41 g, 14.0 mmol, 2 equiv) in 5 mL of CH2Cl2. The reaction was stirred for 2 h at 0 'C. Work-up and fc (1:6) afforded 26 (1.62 g, 6.6 mmol, 94%) as a colourless oil. $R_f(1:8)$ 0.75; IR v 2960, 2940, 2920, 2850, 1760, 1460, 1445, 1435, 1375, 1250, 1070, 990. 910, 825; lH NMR (300 MHZ) 6 1.65 (dd, 3 H, *J =* 0.8.5.8 Hz, CH3). 1.83 (quintet, 2 H, *J =* 6.7 Hx. 2 H-2). 2.12 (q, 2 H, *J* = 6.8 Hz, 2 H-3), 4.36 (t, 2 H, *J* = 6.5 Hz, 2 H-1), 5.35-5.55 (m, 2 H, H-4 and H-5); ¹³C NMR (50 MHz) δ 17.5 (C-6), 27.6 (CH2). 28.1 (CH2). 68.4 (C-l), 89.7 (CCl3). 126.1 (CH=), 128.9 (CH=), 161.6 (CO).

Dichloroacetic acid b-methyl-hex-4-enyl ester (27): According to the general procedure A, a solution of dichloroacetyl chloride (570 mg, 3.9 mmol, 1.1 equiv) and 5-methyl-4-hexen-1-ol (400 mg, 3.5 mmol) in 10 mL of CH2Cl2 was treated with Et3N (707 mg, 7.0 mmol. 2 equiv) in 2 mL of CH2Cl2. The reaction was stirred for 1 h at 0 'C. Work-up and fc (1:lO) afforded 27 (732 mg, 3.25 mmol, 93%) as a light yellow oil. Rf **(1:lO)** 0.55; IR v 2%0, 2920, 2840, 1755, 1440, 1370, 13~,1160,980,905, 810; lH NMR (400 MHZ) 6 1.60 **(s,** 3 H, CH3). 1.70 (s, 3 H, CH3). 1.75 (quintet, 2 H, *J =* 7.3 Hz, 2 H-2). 2.09 (q. 2 H, *J =* 7.3 Hz, 2 H-3), 4.26 (1.2 H, *J =* 6.6 Hz, 2 H-l), 5.09 (tt, 1 H, *J =* 1.3, 7.3 Hz. H-4). 5.94 (s, 1 H, CHCl2); 13C NMR (50 MHZ) 6 17.4 (CH3). 23.8 (CH2). 25.5 (CH3), 28.2 (CH2). 64.2 (CHCl2), 66.9 (C-l), 122.5 (C-4). 132.8 (C-5). 164.3 (CO).

Trichloroacetic acid 5-methyl-hex-4-enyl ester (28): According to the general procedure A, a solution of trichloroacetyl chloride (709 mg, 3.9 mmol, 1.1 equiv) and 5-methyl-4-hexen-l-01(400 mg, 3.5 mmol) in 10 mL of CH2Cl2 was treated with Et3N (707 mg, 7.0 mmol. 2 equiv) in 2 mL of CH2Cl2. The reaction was stirred for 1 h at 0 'C. Work-up and fc $(1:10)$ afforded 28 (858 mg, 3.31 mmol, 95%) as a colourless oil. $R_f(1:10)$ 0.75; IR v 2960, 2920, 2840, 1760, 1440, 1370, 1250,980.900.825,670; lH NMR (400 MHz) 8 1.61 (s, 3 H. CH3). 1.70 (s, 3 H, CH3). 1.80 (quintet, 2 H, J = 6.9 Hz, 2 H-2). 2.12 (q, 2 H, J = 7.2 Hz, 2 H-3), 4.35 (t, 2 H, J = 6.4 Hz, 2 H-1), 5.10 (t, 1 H, J = 7.1 Hz, H-4); ¹³C NMR (50 MHz) δ 17.4 (CH3). 23.8 (CH2). 25.5 (CH3). 28.1 (CH2). 68.6 (C-l), 89.9 (CCl3). 122.4 (C-4). 132.9 (C-5). 161.6 (CO).

Dichloroacetic acid hept-6-en-3.yayl ester (29): To a solution of 3-butyn-l-o1 (2.36 g, 33.7 mmol) in 5.5 mL of DMF were added CuCl (152 mg, 1.53 mmol, **0.05 quiv), K2CO3 (6.34 g, 45.9 mmol,** 1.5 equiv) and n-BuqNCl (861 mg, 3.1 mmol, 0.1 equiv) and under vigorous stirring at r.t., allylbromide (3.7 g, 30.6 mmol, 1.0 equiv) was added dropwise by syringe. The yellow r.m. was stirred for 18 h at r.t., as it turned green slowly. Et 20 (30 mL) was added and the green suspension was filtered over Celite. The filter was rinsed with 50 mL of Et20 and the filtrate was washed with 50 mL of NaCl(aq), dried (Na2SOq), concentrated in vacuo and purified by fc (1:2.5) to afford hept-6-en-3-yn-1-ol¹⁷ (3.49 g, 31.6 mmol, 94%) as a light yellow oil. Rf $(1:2)$ 0.40; IR v 3580, 3440, 3080, 3000, 2940, 2880, 1635, 1415, 910; ¹H NMR (200 MHz) δ 1.91 (bs, 1 H, OH), 2.47 (m, 2 H, 2 H-2). 2.95 (m, 2 H, 2 H-5), 3.70 (f 2 H, J = 6.2 Hz, 2 H-l), 5.10 (dd, 1 H, J = 1.4.9.9 Hz, H-7 cis), 5.30 (dd, 1 H, J = 1.5, 16.9 Hz, H-7 trans), 5.83 (ddt, 1 H, J = 5.3, 9.9, 16.9 Hz, H-6); ¹³C NMR (75.5 MHz) δ 22.6 (CH₂), 22.7 (CH₂), 60.9 (C-1), 78.1 (C-alkyne), 78.9 (C-akyne), 115.5 (C-7). 132.7 (C-6). According to the general procedure A, a solution of dichloroacetyl chloride (411 mg, 2.79 mmol, 1.0 equiv) and hept-6-en-3-yn-1-ol (307 mg, 2.79 mmol) in 5 mL of CH₂Cl₂ was treated with Et3N (564 mg, 5.58 mmol, 2 equiv) in 2 mL of CH₂Cl₂ at 0 °C. The reaction was stirred for 18 h at r.t.. Work-up and fc (1:10) afforded 29 (617 mg, 2.79 mmol, 100%) as a yellow oil. $R_f(1:10)$ 0.45; IR v 3080, 3000, 2900, 1760, 1635, 1460, 1415, 910; ¹H NMR (200 MHz) δ 2.60-2.70 (m, 2 H, 2 H-2), 2.90-3.10 (m, 2 H, 2 H-5), 4.36 (t, 2 H, J = 6.9 Hz, 2 H-1), 5.10 (dq, 1 H, J = 1.6, 9.9 Hz, H-7 cis), 5.30 (dq, 1 H, J = 1.7, 17.0 Hz, H-7 *trans*), 5.80 (dt, 1 H, J = 4.9, 10.1, 17.0 Hz, H-6), 5.97 (s, 1 H, CHCl₂).

Tricbloroacetic acid hept-6-en-3-yoyl ester (30): According to the general procedure A, a solution of trichloroacetyl chloride (495 mg, 2.72 mmol, 1.0 equiv) and hept-6-en-3-yn-1-ol (300 mg, 2.72 mmol) in 9 mL of CH2Cl2 was treated with Et3N (549 mg, 5.44 **mmol,** 2 cquiv) in 2 mL of CH2C12 at 0 'C. The reaction was stirred for 1 h at 0 'C. Work-up and fc (1:10) afforded 30 (617 mg, 2.79 mmol, 100%) as a yellow oil. R_f (1:6) 0.75; IR v 3080, 2980, 2920, 1760, 1630, 1420, 1240, 1005,990,820; lH NMR (200 MHz) 6 2.60-2.75 (m. 2 H, 2 H-2). 2.90-3.00 (m. 2 H, 2 H-5), 4.44 (t. 2 H, J = 6.9 Hz, 2 H-1), 5.10 (dq, 1 H, J = 1.7, 9.9 Hz, H-7 cis), 5.30 (dq, 1 H, J = 1.7, 17.0 Hz, H-7 trans), 5.80 (ddt, 1 H, J = 5.2, 9.9, 17.0 Hz, H-6).

(Z)-Dicbloroacetic acid hepta-3,6-dienyl ester (31): To powdered NaBH4 (2.2 g, 58.1 mmol, 8 equiv) and WC12 (121 mg, 0.68 **mmol.** 0.08 equiv) was slowly added 145 g of dry polyethylene glycol 2001*, followed by 80 mL of CH2Cl2. The mixture was cooled to -10 °C, when hept-6-en-3-yn-1-ol (800 mg, 7.26 mmol, 1 equiv) in 1 mL of CH₂Cl₂ was added in one portion and stirred for 2 h allowing the temperature to rise slowly to r.t. in 2 h. The dark grey r.m. was poured into 300 mL of H₂O and extracted with CH2Cl2 (3 x 80 mL). The organic phases were dried (MgSO4), concentrated and purified by fc (1:2) to afford (Z)hepta-3,6-dien-l-01 (780 mg, 6.95 mmol, 96%) as a colourless oil. *Rf* (1:2) OAO; IB v 3600, 3470, 3080, 3000, 2950. 2930, 2870, 1630, 1045, 995, 910; ¹H NMR (300 MHz) δ 2.29 (q, 2 H, J = 6.7 Hz, 2 H-2), 2.45 (bs, 1 H, OH), 2.80 (t, 2 H, J = 6.8 Hz, 2 H-5), 3.59 (t, 2 H, J = 6.4 Hz, 2 H-1), 4.95 (dt, 1 H, J = 1.5, 10.2 Hz, H-7 *cis*), 5.02 (dq, 1 H, J = 1.7, 17.1 Hz, H-7 *trans*). 5.40-5.57 (m, 2 H, H-3 and H-4). 5.78 (ddt, 1 H, *J =* 6.2, 10.2, 16.9 Hz. H-6): 13C NMR (75.5 MHz) 8 30.5 (CH2). 31.4 (CH2). 61.9 (C-l), 114.7 (C-7), 126.4 (CH=), 129.6 (CH=), 132.8 (C-6). According to the general procedure A, a solution of dichloroacetyl chloride (434 mg, 2.94 mmol, 1.1 equiv) and (Z)-hepta-3,6-dien-1-ol (300 mg, 2.67 mmol) in 9 mL of CH2Cl2 was treated with Et3N (539 mg, 5.3 mmol, 2 equiv) in 2 mL of CH₂Cl₂ at 0 °C. The reaction was stirred for 1 h at 0 °C. Work-up and fc (1:lO) afforded 31 (388 mg, 1.74 mmol, 65%) as a colourless oil. *Rf* (1:s) 0.65; lR v 3080, 3020, 2960, 2920, 2850, 1760, 1635, 1445, 1300, 1165,990; lH NMR (200 MHz) 8 2.48 (q, 2 H, *J =* 6.8 Hz, 2 H-2). 2.82 (t. 2 H. *J =* 6.0 Hz, 2 H-5). 4.28 (t. 2 H, *J =* 6.8 Hz, 2 H-l), 5.00 (d, 1 H, *J =* 11.6 Hz. H-7 cis), 5.04 (d, 1 H, *J =* 17.1 Hz, H-7 *trans),* 5.40-5.65 (m. 2 H, H-3, H-4), 5.81 (ddt, 1 H, *J =* 6.1, 10.1, 17.1 Hz, H-6). 5.94 (s, 1 H, CHC12).

(Z)-Trichloroacetic acid bepta-3,6-dienyl ester (32): According to the general procedure A, a solution of trichloroacetyl chloride (534 mg, 2.94 mmol, 1.1 equiv) and (Z)-hepta-3,6-dien-1-ol (300 mg, 2.67 mmol) in 9 mL of CH2Cl2 was treated with Et3N (539 mg, 5.34 mmol, 2 equiv) in 2 mL of CH2Cl2 at 0 'C. The reaction was stirred for 1 h at 0 'C. Work-up and fc (1:lO) aff&d 32 (424 mg, 1.64 **mmol. 62%) as** a colourless oil. Rf(l:8) 0.80; IB v 3080, 3020, 2960, 2920, 2850, 1760. 1630, 1460, 1250, 1170, 990, 820; ¹H NMR (200 MHz) δ 2.53 (q, 2 H, J = 6.8 Hz, 2 H-2), 2.84 (t, 2 H, J = 6.6 Hz, 2 H-5), 4.36 $(t, 2 H, J = 6.8 Hz, 2 H-1)$, 5.00 (dd, 1 H, J = 1.5, 10.0 Hz, H-7 cis), 5.05 (dd, 1 H, J = 1.5, 16.7 Hz, H-7 trans), 5.40-5.65 (m, 2 H, H-3 and H-4), 5.81 (ddt, 1 H, $J = 6.2$, 10.4, 16.9 Hz, H-6).

Dichloroacetic acid oct-7-en-4-ynyl ester (33): According to the preparation of 29, a solution of 4-pentyn-1-ol **(2.0** g. **23.8 mmol), CuCl** (118 mg, 1.12 mmol, 0.05%). K2CO3 (4.93 g, 35.7 mmol, 1.5 equiv) and TBACl (661 mg, 2.38 mmol, 0.1 equiv) in 4 **mL of DMF was treated with allylbromide (2.61 g. 21.6 mmol. 0.9 equiv)** and **stirred at r.t. for 2 days.17 After work-up and fc (1:4) act-7-en4-yn-l-01 was obtained (2.65 g. 21.34 mmol, 90%) as a light yellow oil. Rf(l:2) 0.40, IR v 3610,3440,3080.3000,2950,2880, 1635, 1430, 1415, 1395,1050,990,910;** lH NMB (200 MHz) 8 **1.59 (bs, 1 H, OH), 1.76** (quintet, 2 H, J = 6.5 Hz, 2 H-2), 2.25-2.40 (m, 2 H, 2 H-3), 2.80-3.00 (m, 2 H, 2 H-6), 3.76 (t, 2 H, J = 6.1 Hz, 2 H-1), 5.09 (dd, 1 H, J = 1.5. 10.0 Hz, **H-8** *cis).* **5.30 (dd, 1 H, J = 1.6, 17.0 Hz, H-8 ~axs). 5.80 (ddt, 1 H. J = 5.2, 10.0. 17.0 Hz. H-7).** According to the general procedure A, a solution of dichloroacetyl chloride (261 mg, 1.77 mmol, 1.1 equiv) and oct-7-en-4-yn-1-ol (200 mg, 1.6 mmol) in 5 mL of CH₂Cl₂ was treated with Et₃N (323 mg, 3.2 mmol, 2 equiv) in 1 mL of CH₂Cl₂ at 0 °C. The reaction was stirred for 2 h at 0 °C. Work-up and fc (1:8) afforded 33 (368 mg, 1.56 mmol, 98%) as a colourless oil. R_f (1:10) **0.35; IR** v **3080, 2960, 2840, 1760, 1740, 1635. 1460, 1415, 1385, 1350, 1300, 1165, 1015, 990, 910, 810; IH NMR (200 MHz**) δ 1.92 (quintet, 2 H, J = 6.6 Hz, 2 H-2), 2.25-2.40 (m, 2 H, 2 H-3), 2.90-3.00 (m, 2 H, 2 H-6), 4.39 (t, 2 H, J = 6.4 Hz, 2 **H-l), 5.10 (dq, 1 H, J = 1.7.9.9 Hz, H-8** *cis),* **5.29 (dq, 1 H, J = 1.8, 16.9 Hz, H-8 rrans), 5.83 (ddt, 1 H, J = 5.3.9.9, 16.9 Hz, H-7), 5.95 (s, 1 H. CHCl2).**

Trichloroacetic acid oct-7-en-4-ynyl ester (34): According to the general procedure A, a solution of trichloroacetyl chloride (644 mg, 3.54 mmol, 1.1 equiv) and oct-7-en-4-yn-1-ol (400 mg, 3.2 mmol) in 10 mL of CH₂Cl₂ was treated with Et3N (646 mg, 6.4 mmol, 2 equiv) in 2 mL of CH₂Cl₂ at 0 °C. The reaction was stirred for 2 h at 0 °C. Work-up and fc (1:8) afforded 34 (862 mg, 3.2 mmol, 100%) as a colourless oil. *Rf* **(1:8) 0.55; IR v 3080,2960,2840, 1760, 1635, 1455. 1415, 1380, 1350,** 1245, 1015, 990, 910, 895, 820; ¹H NMR (200 MHz) δ 1.97 (quintet, 2 H, J = 6.6 Hz, 2 H-2), 2.30-2.45 (m, 2 H, 2 H-3), 2.90-**3.60 (m. 2 H, 2 H-6), 4.48 (t, 2 H, J = 6.3 Hz. 2 H-l), 5.10 (dq, 1 H, J = 1.7.9.9 Ha, H-8 cis), 5.29 (dq, 1 H,** *J =* 1.8, **16.9 Hz, H-8 rruns), 5.83 (ddt, 1 H, J = 5.2.9.9, 16.9 Hz, H-7).**

 $(3R*, 5R^*)$ - and $(3R*, 5S^*)$ -3,5-Dichloro-oxocan-2-one (35): According to the general procedure B, acetate 7 (40) mg, 0.203 mmol) in 2 mL of benzene was treated with 0.3 equiv of CuCl (6.1 x 10⁻⁵ mol, 6.0 mg) and 0.3 equiv of 2,2-bipyridine (6.1 x 10⁻⁵ mol, 9.5 mg) and refluxed for 18 h. Concentration *in vacuo* and purification by fc (1:6) afforded 35 (37 mg, 0.188 mmol, 92%) as a colourless oil. This consisted of an inseparable mixture of the *cis* and *trans* diastereomers in the ratio of 70:30. *Rf* **(1:6) 0.40: IR** v 3000,29&k 1760, 1740, 1460, 1435; MS (El, 70 eV) m/z (relative intensity) 197 **(M++l, 39), 1% (I@, 3). 181 (8). 179 (16). 163 (17). 161 (54). 143 (lo), 125 (100). 115 (29). 103 (51). 100 (59), 79 (55). 69 (23). 68 (37). 41 (28); HRMS calcd for C7H@2Cl2 1%.0058, found 196.0055, calcd** for C7HllO2Cl2 (M++l) 197.0136, found 197.0137. (3R+,SR*)-35a (cis) : ¹H NMR (300 MHz) δ 1.83-2.15 (m, 3 H), 2.33-2.45 (m, 1 H), 2.57 (ddd, J = 11.1, 11.5, 14.0 Hz, H-4), 2.91 (ddd, J = 1.2, 5.8, 14.0 Hz, H-4), 4.10 (ddd, J = 4.1.4.9, 11.1 Hz. H-8). 4.17427 (m, H-8), 4.48 (dd, J = 6.2, 11.5 Hz, H-3). 4.754.88 (m, **H-**5); ¹³C NMR (50 MHz) δ 29.3 (CH₂), 37.7 (CH₂), 50.0 (C-4), 54.6 (CH), 58.6 (CH), 68.0 (C-8), 170.3 (C-2). (3R*,5S*)-35b (trans): ¹H NMR (300 MHz) δ 1.83-2.15 (m, 4 H, 2 CH₂), 2.63 (ddd, 1 H, J = 2.8, 6.6, 14.1 Hz, H-4), 2.88 (ddd, 1 H, J = 4.4.9.1, 14.1 Hz, H-4'). 4.34445 (m, 2 H, 2 H-8), 4.68 (dd, 1 H, *J =* 4.4.6.5 Hz, H-3). 4.45-4.50 (m, 1 H, H-5); 13C NMB (50 MHz) 8 26.7 (CH2). 34.1 (CH2). 46.8 (C-4). 54.3 (CH), 56.6 (CH), 69.0 (C-8), 170.3 (C-2).

Oxocan-2-one (36)²²: To a refluxing solution of HSnBu₃ (148 mg, 0.5 mmol, 2 equiv) in 1.5 mL of cyclohexane was slowly added a solution of 35 (50 mg, 0.25 mmol) and AIBN (0.01 equiv, 0.4 mg) in 1 mL of cyclohexane. The r.m. was refluxed for 1 h, concentrated *in vacuo* and purified by fc (1:6). This afforded 36 (20 mg, 1.44 mmol, 60%) as a colourless oil. R_f (1:6) 0.25. The spectroscopic data were in agreement with the literature.

5-Chloro-oxocan-2-one (37): Oxocan-Zone 35 (281 mg, 1.43 mmol) was dissolved in 7 mL of absolute acetic acid. To this mixture was added at r.t. KI (261 mg, 1.57 mmol, 1.1 equiv), followed by Zn dust (935 mg, 14.3 mmol, 10 equiv) in small portions over 2 h. The r.m. was stirred for 20 h at r.t., poured into 50 mL of H₂O and neutralized by slow addition of 200 mL of NaHCO3(aq). The aqueous phase was extracted with CH2Cl2 (3 x 70 mL), the combined organic phases were dried (MgSO4), concentrated *in vacua* and purified by fc (1:2) to afford 37 (147 mg, 0.904 mmol. 63%) as a colourless oil. *Rf* (1:4) 0.15; IR v 2990.2940, 2850, 1715, 1480, 1440, 1385, 1360, 1350, 1330, 1265, 1135, 1120, 1095, 1085. 1005; lH NMR (300 MHz) 8 1.90-2.00 (m, 2 H. CH2). 2.00-2.10 (m, 2 H. CH2). 2.20-2.40 (m, 2 H. 2 H-4). 2.48 (ddd, 1 H. I = 4.1.7.6, 13.3 Hz. H-3). 2.80 (ddd, 1 H, J = 4.1, 9.9, 13.3 Hz, H-3), 4.20-4.35 (m, 2 H, 2 H-8), 4.44 (ddd, 1 H, J = 3.7, 8.6, 13.0 Hz, H-5); ¹³C NMR (75.5 MHz) 6 27.4 (CH2). 28.1 (CH2). 32.0 (CH2), 36.8 (CH2). 59.1 (C-5). 67.2 (C-8). 175.2 (C-2): MS (EI, 70 eV) m/z (relative intensity) 134 (10), 132 (M⁺-OCH₂, 32), 127 (16), 126 (17), 116 (10), 98 (13), 97 (16), 90 (5), 85 (6), 81 (9), 68 (31), 55 (100), 41 (26). 27 (14).

3S,S-Trichloro-oxoenn-2-one (38): According to the general procedure B, acetate 8 (324 mg, 1.40 mmol) in 20 mL of DCE (O.Cn M) was treated with 0.3 equiv of CuCl(O.42 mmol, 41.6 mg) and 0.3 equiv of 2,2-bipyridine (0.42 mmol, 65.6 mg) and heated in a sealed tube at 130 'C for 2.5 h. Concentration *in vczcuo and* purification by fc (1:lO) afforded 38 (187 mg, 0.808 mmol. 58%) as a colourless oil. *Rf* (1:lO) 0.50; IR v 2960, 1760, 1590, 1460, 1445, 1420, 1180, 1170, 1010: lH NMR (300 MHz, dg-acetone) 8 1.70-2.20 (m, 4 H, 2 CH2). 3.07 (dd, 1 H, J = 3.6.15.4 Hz, H-4), 3.22 (dd, 1 H, J = 8.4, 15.4 Hz, H-4'), 3.70 (t, 2 H, J = 6.2 Hz, 2 H-8), 4.40-4.50 (m, 1 H, H-5); ¹³C NMR (75.5 MHz) δ 26.5 (C-7), 34.9 (C-6), 56.1 (C-5), 56.9 (C-4), 70.8 (C-S), 80.9 (C-3). 168.7 (C-2).

(3R*, 5R*)- and (3R*, 5S*)-3,5-Dichloro-oxonan-2-one (39): According to the general procedure B, acetate 9 $(123 \text{ mg}, 0.58 \text{ mmol})$ in 6 mL of DCE was treated with 0.3 equiv of CuCl $(0.17 \text{ mmol}, 17 \text{ mg})$ and 0.3 equiv of 2,2-bipyridine $(0.17 \text{ mmol}, 27 \text{ mg})$ and refluxed for 18 h. Concentration in vacuo and purification by fc $(1:10)$ afforded 39 (70 mg, 0.33 mmol, 57%) as a colourless oil. This consisted of a mixture of the *cis* and *trans* diastereomers in the ratio of 70:30. R_f (1:6) 0.40; MS (EI, 70 eV) m/z (relative intensity) 211 (M++l, 15). 175 (26). 157 (11). 139 (27). 121(7), 97 (18). 93 (17). 83 (43). 82 (lOO), 81 (30). 67 (35), 55 (52), 54 (40). 41 (27): HRMS calcd for CgH1202C12 210.0214, found 210.0210, calcd for CgH13O2Cl2 (M++l) 211.0293, found 211.0287; (3R*,5R*)-39a (cis): IR v 3010, 2940, 2860, 1760, 1460, 1445, 1175, 1160; ¹H NMR (400 MHz) 6 1.30-1.50 (m. 1 H). 1.65-2.05 (m, 4 H), 2.42 (ddd, 1 H. J = 9.0, 11.8, 14.3 Hz, H-4). 2.75 (ddd, 1 H, J = 1.8. 5.8, 14.4 Hz, H-4'), 4.04 (dt, 1 H, J = 4.0, 11.0 Hz, H-9), 4.25-4.33 (m, 1 H, H-9'), 4.46 (dd, 1 H, J = 6.0, 11.8 Hz, H-3), 4.70-4.85 (m, 1 H, H-5); ¹³C NMR (63 MHz) δ 21.2 (CH₂), 26.6 (CH₂), 39.8 (CH₂), 46.5 (CH₂), 54.4 (CH), 55.0 (CH), 65.8 (C-9), 169.7 (C-2); **(3R*,5S*)-39b (trans): IR v 2940, 1730, 1460, 1370, 1280, 1175, 1040, 990, 905; ¹H NMR (400 MHz)** δ **1.40-1.50 (m, 1** H), 1.60-1.70 (m, 1 H), 1.80-1.90 (m, 2 H), 1.94 (q. 2 H, J = 6.2 Hz), 2.62 (ddd, 1 H, J = 3.2.5.6, 15.4 Hz, H-4). **2.72 (ddd,** 1 H, J = 3.2,8.0, 15.4 Hz. H-4'). 4.33-4.40 **(m.** 1 H, H-5). 4.43-4.50 (m, 2 H, 2 H-9). 4.55 (dd, 1 H, J = 3.2.5.6 Hz, H-3); 13C NMR (63 MHz) 8 19.5 (CH2). 26.6 (CH2). 37.8 (CH2), 43.0 (C-4). 55.0 (CH), 55.7 (CH), 65.5 (C-9). 169.6 (C-2).

Oxonan-2-one (40)²²: According to the preparation of 36, the nine-membered lactone 39 (37 mg, 0.18 mmol) was treated with HSnBu3 (2 equiv, 0.36 mmol) and AIBN (5%) in 1 mL of refluxing cyclohexane for 6 h. Work-up and fc (1:10) yielded 40 (14 mg, 0.1 mmol, 55%). *Rf* (1:lO) 0.50. The spectroscopic data were in agreement with the literature.

3,3,5-Trichloro-oxonan-2-one (41): According to the general procedure B, acetate 10 (100 mg, 0.41 mmol) in 6.7 **mL of DCE (0.06 M) was treated with 0.3 equiv** of CuCl(O.12 mmol, 12.1 mg) and 0.3 equiv of 2f-bipyridine (0.12 mmol, 18.7 mg) and heated in a sealed tube at 190 °C for 2 h. Concentration in vacuo and purification by fc (1:12) afforded 41 (59 mg, 0.24 mmol, 59%) as a colourless oil. R_f (1:10) 0.40; IR v 3030, 2980, 2890, 1770, 1470, 1440, 1385, 1300, 1270; ¹H NMR (300 MHz) δ 1.70-1.95 (m, 5 H), 2.00-2.15 (m, 1 H), 3.05 (dd, 1 H, J = 3.7, 15.1 Hz, H-4), 3.14 (dd, 1 H, J = 8.4, 15.1 Hz, H-4'). 4.35-4.47 (m, 2 H, 2 H-9), 4.50-4.60 (m, 1 H, H-5); 13C NMR (75.5 MHz) 8 19.0 (CH2). 26.4 (CH2), 37.5 (CH2). 54.2 (C-4), 55.2 (C-5), 67.1 (C-9). 81.6 (C-3). 165.8 (C-2).

(3R*, 5R*, 8R*)-, (3R*, 5S*, 8R*)- and (3R*, 5R*, 8S*)-3, 5-Dichloro-8-methyl-oxocan-2-one (42): **According to the general procedure** B, acetate 16 (100 mg, 0.47 mmol) in 6 mL of DCE (0.08 M) was treated with 0.3 cquiv of CuCl (0.14 mmol, 14.0 mg) and 0.3 equiv of 2,2-bipyridine (0.14 mmol, 21.9 mg) and heated in a sealed tube at 130 'C for 4 h. Concentration in vacuo and purification by fc (1:5) afforded 42 (67 mg, 0.32 mmol, 68%) as a light yellow oil, which solidified upon standing. The product consisted of a mixture of three diastereomers in the ratio of 70:20:10. $R_f(1:5)$ 0.40; IR v 2920, 1755, 1440, 1110, 990, 840; (3R*,SR*,ftR*)42a (major isomer): lH NM.8 (300 MHZ) 8 1.33 (d, 3 H, *J =* 6.3 Hz, CH3), 1.70-2.00 (m, 3 H, 2 H-6, H-7), 2.39 (ddd, 1 H, *J* = 1.3, 7.5, 10.0 Hz, H-7'), 2.55 (dt, 1 H, *J* = 11.3, 13.6 Hz, H-4), 2.90 (dd, 1 H, *J* = 6.4, 13.5 Hz, H-4'), 4.18 (ddt, 1 H, *J* = 1.7, 6.7, 11.1 Hz, H-5), 4.50 (dd, 1 H, *J* = 6.5, 11.5 Hz, H-3), 5.16 (ddq, 1 H, *J* = 3.7, 6.3, 10.1 Hz, H-8); ¹³C NMR (75.5 MHz) δ 19.8 (CH₃), 37.4 (CH₂), 38.0 (CH₂), 51.2 (C-4), 54.8 (CHCl), 59.0 (CHCl), 76.3 (C-8), 171.6 (C-2); $(3R*, 5S*, 8R*)$ -42b (second isomer): ¹H NMR (300 MHz) δ 1.37 (d, 3 H, $J = 6.2$ Hz, CH3), 2.67 (dd, 1 H, H-4). 5.0-5.10 (m. 1 H, H-8). rest of the signals obscured; 13C NMR (75.5 MHZ) 8 20.0 (CH3). 31.7 (CH2). 32.6 (CH2). 47.7 (C-4) 55.5 (CHCl), 57.2 (CHCl), 76.7 (C-8), 171.6 (C-2); $(3R^*5R^*8S^*)$ -42c (minor isomer): ¹H NMR (300 MHz) δ 1.43 (d, 3 H, $J = 6.2$ Hz, CH₃), 4.75 (dd, 1 H, H-3), rest of the signals obscured; ¹³C NMR (75.5 MHz) δ 20.2 (CH₃), 35.1 (CH₂), 36.0 (CH2). 45.7 (C-4). 53.4 (CHCl), 56.4 (CH), 78.4 (C-8). 171.6 (C-2).

lactone	43a	44a	46	51a
crystal type	monoclinic	monoclinic	monoclinic	monoclinic
space group	C2/c	P2 ₁ /a	P21/n	P21/n
$ a(\AA) $	29.605(3)	10.3946(8)	6.3772(9)	6.467(3)
b(A)	5.7972(6)	9.9835(6)	11.3992(8)	10.862(2)
c(A)	19.787(1)	11.469(2)	16.139(1)	13.464(2)
β ()	128.610(5)	111.933(8)	92.139(9)	95.47(2)
$\left \nu \right\rangle$ (Å ³)	2653.6(4)	1104.0(2)	1172.0(2)	941.5(5)
Iz	8	4	4	4
calcd density ($gcm-3$)	1.37	1.35	1.47	1.49
μ (CuK α) (cm ⁻¹)	43.9	51.5	70.44	60.01
F(000)	1136	472	536	440
T(K)	293	253	247	247
final R	0.058	0.061	0.049	0.061
observed reflections	2184	1705	2231	1519
dihedral angle (°)				
$(C3)-(C2)-(O1)-(C8)$	142	143	140	4

Table 5: Selected data of the crystal structures of lactones 43a, 44a, 46 and **51a**

 $(3R^*, 5R^*, 8S^*)$ -, $(3R^*, 5S^*, 8S^*)$ - and $(3R^*, 5R^*, 8R^*)$ -3,5-Dichloro-8-phenyl-oxocan-2-one (43): According to the general procedure B, acetate 17 (100 mg, 0.37 mmol) in 1.8 mL of benzene (0.2 M) was treated with 0.3 equiv of CUCI (0.11 mmol, 10.9 mg) and 0.3 equiv of 2,2-bipyridine (0.11 mmol, 17.3 mg) and heated in a sealed tube at 180 'C for 1.75 h. Concentration *in vacuo* and purification by fc (1:8) afforded 43 (50.8 mg, 0.186 mmol, 51%) as a yellow solid, which consisted of three diastereomers in the ratio of 69:18:13. Rf(1:8) 0.45; IR v 3060, 3010, 2950, 2920, 1760, 1490, 1445, 1350; The major cis-dichloro, trans-phenyl isomer could be isolated by crystallization from hexane. $(3R^*, 5R^*, 8S^*)$ -43a (major isomer): light yellow crystals, mp 71-76 'C (hexane); a sample of these crystals was subjected to an X-ray analysis (Figure 1, Table $5)^{24}$; ^{1}H NMR (300 MHz) 8 2.0-2.15 (m, 2 H, 2 H-6). 2.15-2.25 (m, 1 H, H-7). 2.45-2.55 (m, 1 H, H-7). 2.66 (dt, 1 H, *J =* 11.4, 13.6 Hz, H-4), 3.01 (dd, 1 H, $J = 6.4$, 13.6 Hz, H-4'), 4.31 (ddt, 1 H, $J = 6.5$, 11.2 Hz, H-5), 4.62 (dd, 1 H, $J = 6.5$, 11.5 Hz, H-3), 6.05 (dd, 1 H, *J =* 7.0.7.6 I-Ix, H-8). 7.30-7.45 (m, 5 H, Ar): 13C NMR (50 MHz) 8 37.9 (CH2). 38.3 (CH2). 51.5 (C-4). 54.7 (CH), 59.2 (CH), 80.6 (C-8), 125.9, 125.9, 128.3, 128.5, 138.0, 171.3 (C-2). MS (EI, 70 eV) m/z (relative intensity) 272 (M⁺, 25), 237 (5). 200 (2). 169 (16). 168 (18). 167 (25). 166 (27). 140 (24). 138 (SO), 117 (74). 105 (60). 91 (30). 77 (22). 67 (9). 55 (100). 41 (13); HRMS calcd for C₁₃H₁₄O₂Cl₂ 272.0371, found 272.0370; Anal. Calcd. for C₁₃H₁₄O₂Cl₂: C, 57.16; H, 5.17; Cl, 25.96. Found C, 57.13; H, 5.26; Cl, 26.15; $(3R*, 5S*, 8S*)-43b$ (second isomer): ¹H NMR (300 MHz) δ 2.00-2.20 (m, 3 H), 2.82 (m, 1 H), 2.65-3.01 (m, 2 H, 2 H-4). 4.30 (m, 1 H, H-5). 4.85 (dd, 1 H, *J =* 4.5.6.7 I-Ix, H-3), 5.96 (dd, 1 H, *J =* 3.5.9.2 Hx, H- 8). 7x-7.45 (m, 5 H. Ar); *13C Whir* (50 MHz) 8 35.7 (CH2). 36.9 (CHZ). 48.2 (C-4). 54.0 (CH), 57.3 (CH), 80.7 (c-8). 125.7, 125.9, 128.3, 128.5, 138.0, C-2 not observed; $(3R^*, 5R^*, 8R^*)$ -43c (minor isomer): ¹H NMR (300 MHz) δ 2.00-2.20 (m, 3 H), 2.80-2.90 (m, 1 H), 2.65-3.01 (m, 2 H, 2 H-4), 4.05 (m, 1 H, H-5), 4.80-4.90 (m, 1 H, H-3), 5.80 (dd, 1 H, J = 3.4, 9.7 Hz, H-8). 7.30-7.45 (m, 5 H, Ar); 13c NME (50 MHz) 8 33.2 (CH2). 2 CH2 obscured, 52.0 (CH), 56.3 (CH), 82.6 (C-8). 125.9, 126.1 128.3, 128.5, 138.0, C-2 not observed.

(3R,SR*)-* **and** (3R*,SS*)-3,5-Dicltloro-7,7-dimctbyl-oxoean-Z-one (44): According to the general procedure B, acetate 19 (200 mg, 0.89 mmol) in 4.5 mL of benzene (0.2 M) was treated with 0.3 equiv of CuCl (0.27 mmol, 26.3 mg) and 0.3 equiv of 2,2-bipyridine $(0.27 \text{ mmol}, 42.2 \text{ mg})$ and heated in a sealed tube at 180 °C for 1.5 h. Concentration *in vacuo* and purification by fc (1:8) afforded 44 (162.5 mg, 0.72 mmol, 81%) as a white solid, which consisted of two diastereomers in the ratio of 70:30. R_f (1:8) 0.45; The major cis-isomer could be isolated by recrystallization from hexane. $(3R^*, 5R^*)$ -44a (cis): white crystals, mp 78-81 [']C (hexane), a sample of these crystals was subjected to an X-ray analysis (Figure 3, Table 5)^{9a}; IR v 2960, 2920, 2870, 1750, 1455, 1250, 1140, 1000, 880, 725; ¹H NMR (300 MHz) δ 0.86 (s, 3 H, CH₃), 1.20 (s, 3 H, CH₃), 1.91 (dd, 1 H, $J = 6.6$, 16.4 Hz, H-6), 2.09 (d, 1 H, $J = 16.4$ Hz, H-6'), 2.47 (dt, 1 H, $J = 11.5$, 13.4 Hz, H-4), 2.90 (dd, 1 H, $J = 6.3$, 13.4 Hz, H-4'), 3.59 (d, 1 H, J = 11.0 Hz, H-8), 4.35-4.45 (m, 1 H, H-5), 4.52 (dd, 1 H, J = 6.4, 11.7 Hz, H-3), 4.58 (d, 1 H, J = 11.0 Hz, H-8'); ¹³C NMR (75.5 MHz) δ 23.6 (CH₃), 26.9 (CH₃), 38.1 (C-7), 51.2 (CH₂), 51.6 (CH₂), 54.0 (CH), 54.5 (CH), 76.3 (C-8). 171.6 (C-2); MS (EL 70 eV) m/z (relative intensity) 225 (M++l, 10). 207 (26). 206 (38). 191 (33). 189 (lOO), 170 (15). 153 (61). 152 (67), 134 (48). 107 (38). 99 (lOO), 95 (40). 81 (36). 69 (44). 55 (70). 43 (56). 41 (47). 36 (42); HEMS calcd for C9H₁₄O₂³⁵Cl (M⁺-Cl) 189.0682, found 189.0689, calcd for C9H₁₄O₂³⁷Cl (M⁺-Cl) 191.0653, found 191.0649; Anal. Calcd. for C9Hl402Cl2: C, 48.02: H, 6.27; Cl, 31.50. Found C, 48.07; H, 6.34; Cl, 31.41; **(3R*,SS*)-44b (rrans): IR v 2980, 2860, 1740, 1460, 1365, 1290,** 1260, 1155, 1040, 1030, 905. 945, 875; lH NMB (400 MHz) 8 0.90 (s, 3 H, CH3), 1.25 (s, 3 H, CH3), 1.91 (dd, 1 H, J = 7.4, 16.4 Hz, H-6), 2.10 (dd, 1 H, J = 1.2, 16.4 Hz, H-6'), 2.70-2.75 (m, 2 H, 2 H-4), 3.82 (d, 1 H, J = 11.2 Hz, H-8), 4.48 (d, 1 H, J = 11.2, H-8'), 4.50-4.53 (m, 1 H, H-3), 4.56-4.61 (m, 1 H, H-5); ¹³C NMR (75.5 MHz) δ 23.5 (CH3), 27.0 (CH3), 38.3 (C-7), 49.1 (CH2), 50.8 (CH2), 52.6 (CH), 54.3 (CH), 76.8 (C-8), 170.9 (C-2).

7,7-Dimethyl-oxocan-2-one (45): To a refluxing solution of 44 (105 mg, 0.47 mmol) in 4.5 mL of benzene was added in small portions via a syringe pump a solution of HSnBu3 (339 mg, 1.17 mmol, 2.5 equiv) and AIBN (3.8 mg, 2.3×10^{-5} mol. 0.05 equiv) in 3 mL of benzene over a period of 1 h. After one hour of reflux the solvent was evaporated and the residue taken up in 30 mL of CH2Cl2. This solution was shaken with 10 mL of KF(aq), the aqueous layer was separated and washed with CH₂Cl₂ (2 x 10 mL). After drying of the organic layers (Na₂SO₄) and concentration in vacuo, the residue was purified by fc (1:3) affording 45 (42 mg, 0.27 mmol, 58%) as a colourless oil. Rf (1:6) 0.20; IR v 2960, 2930, 2860, 1770, 1480, 1450, 1370, 1330, 1310, 1250, 1150, 1120, 1060; ¹H NMR (250 MHz) δ 0.91 (s, 6 H, 2 CH3), 1.20-1.40 (m, 3 H, 2 H-4 and H-5), 1.45-1.60 (m, 1 H, H-5'), 1.70-1.85 (m, 2 H, 2 H-6), 2.45-2.55 (m, 2 H, 2 H-3), 3.90 (bs, 2 H, 2 H-8); ¹³C NMR (75.5 MHz) δ 22.1 (C-5), 25.1 (CH3), 25.2 (CH3). 27.8 (CH2). 31.4 (CH2). 35.6 (C-7). 37.4 (C-3) 75.4 (C-8). 176.1 (C-2).

3,3,5-tricbloro-7,7-dimethyl-oxoean-2-one (46): According to the general procedure B, acetate 28 (934 mg, 3.6 mmol) in 18 mL of DCE (0.2 M) was treated with 0.3 equiv of CuCl (1.08 mmol, 107 mg) and 0.3 equiv of 2,2-bipyridine (1.08 mmol, 169 mg) and heated in a sealed tube at 145 °C for 2 h. Concentration *in vacuo* and purification by fc (1:30) afforded a white solid, which was recrystallized from hexane to yield 46 (628 mg, 2.42 mmol, 67%) as white crystals, mp 68-69 'C, a sample of these crystaB was subjected to an *X-ray analysis* (Figure 4, Table 5).24Rf(l:10) 0.55; IB v 3020,2960, 1760, 1465, 1370, 1250, 1070, 1030; lH NMB (300 MHz) 8 0.90 (s. 3 H, CH3), 1.27 (s, 3 H, CH3), 1.91 (dd, 1 H, J = 6.7, 16.5 Hz, H-6), 2.14 (dd, 1 H, $J = 1.1, 16.5$ Hz, H-6'), 2.98 (dd, 1 H, $J = 10.7, 14.6$ Hz, H-4), 3.23 (dt, 1 H, $J = 1.3, 14.6$ Hz, H-4'), 3.79 (dd, 1 H, $J = 1.1, 10.7$ Hz, H-8), 4.55 (d, 1 H, J = 10.7 Hz, H-8'), 4.56 (m, 1 H, H-5); ¹³C NMR (75.5 MHz, d₆-acetone) δ 24.3 (CH3), 25.2 (CH3), 36.3 (C-7), 48.0 (CH2), 54.8 (CH2), 56.1 (C-5), 71.2 (C-8), 84.4 (C-3), 166.6 (C-2); Anal. Calcd. for C9H13O2Cl3: C, 41.64; H, 5.05; Cl, 40.98. Found C, 41.78; H, 5.17; Cl, 40.88.

(3R,SS*)-* **and (3R*,5R*)-3,5-Dichloro-6,6-dimethyl-oxocan-2-one (47):** According to the general procedure B, acetate 21(650 mg, 2.89 mmol) in 25 mL of benzene was treated with 0.3 equiv of CuCl(O.87 mmol, 86 mg) and 0.3 equiv of 2,2-bipyridine (0.87 mmol, 136 mg) and heated in a sealed tube at 120 'C for 18 h. Concentration *in vacua* and purification by fc

 $(1:20)$ afforded 47 (487 mg, 2.16 mmol, 75%) of a colourless oil, which consisted of two inseparable diastereomers in the ratio of 7030. Rf(l:lO) 0.25; IB v 2960. 2920, 1760, 1465, 1445, 1375, 1275, 1165, 1140, 1035, 965, 810; MS (EI, 70 eV) m/z (relative intensity) 225 (M++l, 6). 211 (3). 209 (3). 200 (4) 199 (4). 197 (6). 191 (3). 190 (3). 189 (lo), 172 (7). 170 (11). 166 (7). 164 (30). 163 (8). 162 (QO), 161 (18), 150 (14). 125 (19). 103 (22). 90 (33). 83 (99). 75 (45). 69 (100). 55 (60). 41(77). 39 (57); HEM8 calcd for CQH1502Cl2 (M++l) 225.0449, found 225.0438; for **CQH1402Cl (M+-Cl)** 189.0683. found 189.0653; $(3R*,5S^*)$ -47a (cis): ¹H NMR (400 MHz) δ 1.03 (s, 3 H, CH₃), 1.20 (s, 3 H, CH₃), 1.35 (dt, 1 H, J = 2.0, 16.1 Hz, H-7), 1.96 (ddd, 1 H, $J = 4.3$, 12.7, 16.8 Hz, H-7'), 2.45 (ddd, 1 H, $J = 7.9$, 12.0, 15.3 Hz, H-4), 2.71 (ddd, 1 H, $J = 1.0$, 5.4, 15.3 Hz, H-4'), 4.07 (ddd, 1 H, J = 2.1, 11.5, 13.5 Hz, H-8), 4.47 (dd, 1 H, J = 3.2, 8.1 Hz, H-5), 4.55 (dd, 1 H, J = 5.4, 12.0 Hz, H-3), 4.64 (ddd, 1 H. J = 1.8.4.3, 11.5 Hz, H-8'); 13C NME (100.6 MHZ) 6 25.7 (CH3), 25.7 (CH3). 38.2 (C-7). 37.2 (C-6), 43.2 (C-4). 56.4 (CH), 65.7 (C-8). 67.0 (CH), 171.7 (C-2): **(3R*,SR*)-47b (rrrms):** 1H NMB (400 MHZ) 8 1.10 (s, 3 H. CH3). 1.16 (s, 3 H, CH3), 1.30 (dt, 1 H, J = 3.2, 15.6 Hz, H-7), 2.29 (ddd, 1 H, J = 5.3, 12.0, 16.4 Hz, H-7'), 2.60 (ddd, 1 H, J = 4.7, 7.1, 15.2 Hz, H-4), 2.70 (ddd, 1 H, J = 1.7, 8.9, 15.2 Hz, H-4'), 4.20 (dd, 1 H, J = 1.8, 6.0 Hz, H-5), 4.32 (dt, 1 H, J = 3.4, 11.2 Hz, H-8), 4.44 (dd, 1 H, J = 3.0, 5.1 Hz, H-3), 4.60-4.65 (m, 1 H, H-8'); ¹³C NMR (100.6 MHz) δ 24.0 (CH3), 24.5 (CH3), 38.6 (C-7), 38.3 (C-Q, 41.9 (C-4). 53.4 (CH), 65.3 (C-8). 67.1 (CH), 172.0 (C-2).

3,3.5-Trichloro-6,6-dimethyl-oxocan-2-one (48): According to the general procedure B, acetate 22 (750 mg, 2.90) **mmol) in 26** mL of DCE was treated with 0.3 equiv of CuCl(O.87 mmol. 86 mg) and 0.3 equiv of 2,2-bipyridine (0.87 mmol. 136 mg) and heated in a sealed tube at 110 °C for 18 h. Concentration in vacuo and purification by fc (1:20) afforded a light yellow solid, which was recrystallized from hexane to yield 48 (371 mg, 1.42 mmol, 50%) as white crystals. $R_f(1:10)$ 0.35; IR v 2960, 2920, 1760, 1460, 1420, 1390, 1370, 1240, 1180, 1150, 1060, 1040, 995, 975, 920, 895, 845; ¹H NMR (400 MHz) δ 1.03 (s, 3 H, CH3), 1.23 (s, 3 H, CH3), 1.43 (dt, 1 H, J = 2.0, 16.2 Hz, H-7). 1.88 (dt, 1 H, J = 3.1, 16.0 Hz, H-7'). 2.86 (dd, 1 H, J = 7.7, 16.3 Hz, H-4), 3.05 (d, 1 H, J = 16.3 Hz, H-4'), 4.22 (dt, 1 H, J = 2.2, 11.5 Hz, H-8), 4.66 (ddd, 1 H, J = 2.1, 4.3, 11.4 Hz, H-8'), 4.60-4.70 (m, 1 H, H-5); ¹³C NMR (100.6 MHz) δ 26.1 (CH3), 26.1 (CH3), 38.1 (C-6), 38.4 (C-7), 52.4 (C-4), 65.5 (C-5), 67.2 (C-8). 82.6 (C-3). 167.7 (C-2): Anal. Calcd. for CgHl302Cl3: C, 41.64; H, 5.05; Cl, 40.98. Found C, 41.75; H, 4.99; Cl, 40.82.

(3R,SR*)-* **and (3R*,SS*)-3,5-Dichloro-5-methyl-oxocan-2-one (49):** According to the general procedure B, acetate 23 (164 mg, *0.78* mmol) in 7.8 mL of benzene was treated with *0.3* equiv of CuCl (0.23 mmol, 23 mg) and 0.3 equiv of 2,2-bipyridine (0.23 mmol, 36 mg) and heated in a sealed tube at 150 °C for 1 h. Concentration *in vacuo* and purification by fc (1:25) afforded 49 (84.9 **mg,** 0.40 mmol, 52%) as a colourless oil, which consisted of two diastereomers in the ratio of 73:27. A pure fraction *(47* mg, *0.22* mmol, 28%) of the major isomer could be isolated by fc (1:25). *(3R*,5R*)-49a (cis):* colourless oil; *Rf* (1:10)0.30; IEv3020,2960, 2920, 2835, 1760, 1745, 1460, 1440, 1375, 1365, 1310, 1260, 1160, 1100, 1040, 1020,990, %5,930,%5,855; lH NME (400 MHZ) 8 1.72 *(s. 3* H, CH3), 1.92 (tt, 1 H,J = 5.9.9.7 Hz), 2.00-2.10 (m. 2 I-I), 2.18 (dd, 1 H, $J = 10.2$, 14.5 Hz, H-6), 2.67 (dd, 1 H, $J = 4.7$, 13.9 Hz, H-4), 2.92 (dd, 1 H, $J = 11.5$, 13.8 Hz, H-4'), 4.28 (dd, 1 H, $J = 4.7$, 11.4 Hz, H-3). 4.40-4.50 (m, 2 H, 2 H-8): 13C NMB (100.6 MHZ) 8 26.8 (CH2). 30.8 (CH3). 40.3 (CH2). 52.3 (CH2), 52.6 (C-3), 69.7 (C-8), 70.6 (C-5), 173.0 (C-2); $(3R^*$, $5S^*)$ -49b $(trans):$ R_f (1:10) 0.25; ¹H NMR (400 MHz) δ 1.70 (s, 3 H, CH3), 1.75-1.90 (m, 1 H), 1.92 (ddd, 1 H, J = 2.2, 11.0, 16.0 Hz, H-6), 2.07 (ddd, 1 H. J = 2.3, 7.2, 15.6 Hz, H-6'), 2.05-2.15 (m, 1 H), 2.56 (dd, 1 H, J = 9.9, 14.6 Hz, H-4), 2.71 (dd, 1 H, J = 4.2, 14.6 Hz, H-4'), 4.40 (ddd, 1 H, J = 4.9, 6.2, 11.3 Hz, H-8), 4.51 (ddd, 1 H, J = 4.2, 7.6, 11.7 Hz, H-8'), 4.74 (dd, 1 H, J = 4.2, 9.9 Hz, H-3); ¹³C NMR (100.6 MHz) δ 26.9 (CH₂), 36.1 (CH₃), 38.9 (CH2). 52.2 (CH2), 52.7 (C-3). 68.6 (C-8). 70.1 (C-5). 172.9 (C-2).

3,3,5-Trichloro-S-methyl-oxocan-2-one (50): According to the general procedure B, acetate 24 (907 mg, 3.69 mmol) in 36 mL of DCE was treated with 0.3 equiv of CuCl (1.11 mmol, 110 mg) and 0.3 equiv of 2,2-bipyridine (1.11 mmol, 173 mg) and heated in a sealed tube at 120 °C for 2 h. Concentration *in vacuo* and purification by fc (1:20) afforded a colourless oil, which solidified upon standing to yield 50 (516 mg, 2.10 mmol, 57%). R_f (1:10) 0.35; IR v 2960, 2930, 1760, 1450, 1450, 1380, 1365, 1290, 1250, 1190, 1165. 1150, 1120, 1110, 1090, 1060, 1035,990, 930,910, 870, 690; lH NMB (400 MHz) 8 1.80 (s, 3 H, CH3). 1.80-1.90 (m, 1 H, H-7). 1.91 (dd, 1 H. J = 9.4, 16.5 Hz, H-6), 2.10-2.25 (m, 1 H, H-7'), 2.17 (dd, 1 H, J = 6.7, 16.6 Hz, H-6'), 3.14 (d, 1 H, J = 14.9 Hz, H-4), 3.51 (d, 1 H, J = 14.8 Hz, H-4'), 4.37 (td, 1 H, J = 4.4, 14.9 Hz, H-8), 4.67 (dt. 1 H, J = 3.5, 10.6 Hz, H-8'); ¹³C NMR (100.6 MHz) δ 26.1 (CH₂), 33.5 (CH₂), 39.8 (CH₂), 59.5 (C-4), 70.7 (C-5), 71.2 (C-8), 80.2 (C-3), 169.3 (C-2); MS (FAB, 70 eV) m/z (relative intensity): 245 (M⁺+1, 3), 209 (M⁺-Cl, 5), 167 (16), 155 (31), 149 (53), 139 (20), 138 (38), 137 (71), 136 (73), 121 (16), 107 (32), 97 (34), 95 (41), 83 (58), 81 (44), 71 (42), 69 (67), 57 (68), 55 (69). 43 (43). 41 (37).

(3R*,4S*,5R*)-, (3R*,4S*,5S*)-, (3R*,4R*,5R*)- and (3R*,4R*,5S*)-3,5-Dichloro-4-methyl**oxocan-tone (51): According to the general procedure** B, acetate **25 (135** mg, 0.64 mmol) **in 3.2 mL of benzene was treated with 0.3** equiv of CuCl(O.19 mmol, 19 mg) and 0.3 equiv of 2,2-bipyridine (0.19 mmol, 30 mg) and heated in a sealed tube at 120 'C for 20 h. Concentration *in vacua* and filtration over a short Si-column (1:20) afforded 51 (65 mg, 0.308 **mmol,** 48%) as a colourless oil, which consisted of four diastereomers in the ratio of 60:20:10:10. The major isomer **51a could be isolated by** recrystallization from hexane. Isomer 51b could be separated by fc $(1:20)$ ($R_f(1:8)$ 0.25) from the mixture of the two minor isomers **51c** and **51d** (R_f (1:8) 0.22), which could not be separated from each other. $(3R^*, 4S^*, 5R^*)$ -51a: mp 96-98 °C, white crystals, a sample of these crystals was subjected to an X-ray analysis (Figure 5, Table $5)^{24}$; IR v 3020, 2970, 2940, 2880, 1760, 1465, 1380, 1365, 1300, 1240, 1160, 1020, 970, 955, 910; ¹H NMR (300 MHz) δ 1.40 (d, 3 H, J = 6.6 Hz, CH3), 1.90-2.10 (m, 3 H), 2.15-2.30 (m, 1 H), 2.43 (tq, 1 H, J = 6.6.9.7 Hz, H-4). 3934.02 (m, 1 H, H-5), 4.07 (d, 1 H, J = 9.5 Hz, H-3). 4.26 (ddd, 1 H, J = 4.7, 5.1, 11.1 Hz, H-8). 4.78 (dt, 1 H, J = 6.7, 11.1 Hz, H-8'); l3C NMB (75.5 **MHz) 6** 19.6 (CH3). 26.8 (CH2). 35.7 (CH₂), 50.7 (C-4), 60.8 (CH), 65.4 (CH), 68.0 (C-8), 172.2 (C-2); MS (EI, 70 eV) m/z (relative intensity) 211 (M⁺+1, 5), 175 (17). 161 (7) 139 (12). 135 (16). 117 (27). 110 (23). 108 (69). 89 (55), 83 (29). 82 (lOO), 81 (44). 67 (52). 55 (@I), 41 (44); HRMS calcd for C8H12O2Cl2 210.0214, found 210.0249; Anal. Calcd. for C8H12O2Cl2: C, 45.52; H, 5.73. Found C, 45.42; H, 5.76; (3R*,4S*,SS*)-Sib (second isomer): colourless oil; IR v 3020, 2960, 2940, 1740, 1460, 1450, 1380, 1290, 1265, 1230, 1160, 1130, 1080, 995, 980, 965, 930, 905, 880; ¹H NMR (300 MHz) δ 1.29 (d, 3 H, J = 6.8 Hz, CH3), 1.70-2.30 (m, 4 H, 2 H-6 and 2 H-7). 2.87 (ddq, 1 H, J = 3.5.6.8.8.8 Hz, H-4) 4.15 (dt, 1 H, J = 6.4.8.7 Hz, H-5), 4.35 (dd, 1 H, J = 5.0, 11.7 Hz, H-8), 4.59 (ddd, 1 H, J = 4.1, 8.8, 11.7 Hz, H-8'), 4.85 (d, 1 H, J = 3.5 Hz, H-3); ¹³C NMR (75.5 MHz) δ 16.4 (CH3), 25.9 (CH2). 31.8 (CH2). 45.7 (C-4). 58.8 (CH), 63.3 (CH), 69.9 (C-8). 172.2 (C-2): **(3Rf,4R+,5R')-Sic and (3R*,4R*,SS*)-** 51d: ¹H NMR (300 MHz) δ 1.25 (d, 3 H, J = 7.0 Hz, CH₃) and 1.32 (d, 3 H, J = 6.9 Hz, CH₃), the rest of the ¹H signals was *obscured;* **(3R*,4R*,5R*)-51c**: ¹³C NMR (75.5 MHz) δ 17.8 (CH₃), 26.8 (CH₂), 29.6 (CH₂), 48.7 (C-4), 59.2 (CH), 63.6 (CH), 67.4 (C-8), 172.2 (C-2): $(3R^*4R^*5S^*)-51d$: $13C$ NMR (75.5 MHz) δ 20.1 (CH3), 25.9 (CH2), 32.4 (CH2), 49.9 (C-4), 58.9 (CH), 63.3 (CH), 68.0 (C-8), 170.4 (C-2).

(4R*,5SS)-3,3,5-Trichloro-4-methyl-oxocan-2-one (52): According to the general procedure B, acetate 26 (165 mg, 0.64 mmol) in 6.4 mL of BCE was treated with 0.3 equiv of CuCl(O.19 **mmol,** 19 mg) and 0.3 equiv of 2,2-bipyridine (0.19 mmol, 30 mg) and heated in a sealed tube at 170 °C for 20 h. Concentration *in vacuo* and purification by fc (1:30) afforded 52 (52.2 mg, 0.213 mmol, 33%) as a colourless oil. *Rf* (1:lO) 0.35; lB v 3000,2960,2940. 1760, 1590, 1465, 1450, 1435, 1380, 1370, 1360, 1350, 1300, 1230, 1085, 1073, 1010, 965, 930, 890; ¹H NMR (250 MHz) δ 1.55 (d, 3 H, J = 6.4 Hz, CH3), 1.63 (dd, 1 H, $J = 1.4, 6.0$ Hz, H-7), 1.70-1.80 (m, 1 H, H-7'), 1.86 (ddd, 1 H, $J = 2.6, 9.5, 17.3$ Hz, H-6), 2.21 (ddd, 1 H, $J = 3.3, 8.9, 17.4$ Hz, H-6'), 3.06 (dq, 1 H, J = 6.4, 10.0 Hz, H-4), 3.98 (ddd, 1 H, J = 2.9, 3.9, 10.0 Hz, H-5), 4.35 (ddd, 1 H, J = 1.2, 5.9, 10.9 Hz, H-8), 4.77 (ddd, 1 H, J = 3.5, 11.0, 12.3 Hz, H-8'); ¹³C NMR (75.5 MHz) δ 15.6 (CH3), 24.4 (CH2), 31.7 (CH2), 51.9 (C-4), 64.0 (C-5). 71.6 (C-8) 86.8 (C-3). 170.6 (C-2).

3,3,5-Trichloro-oxa-7-cyclodecyn-2-one (53): According to the general procedure B, acetate 30 (100 mg, 0.39 mmol) in 3.9 mL of DCE was treated with 0.3 equiv of CuCl (0.12 mmol, 11.6 mg) and 0.3 equiv of 2.2-bipyridine (0.12 mmol, 18.7 mg) and heated in a sealed tube at 120 'C for 20 h. Concentration *in vucuo* and purification by fc (1:lO) affotded 53 (36 mg, 0.14 mmol, 36%) as a colourless oil. Rf(1:10) 0.30; IR v 2980, 2920, 2840, 1745, 1590, 1460, 1420, 1370, 1180, 1075, 1030, 990, 890, 820; ¹H NMR (300 MHz, CDCl₃) δ 2.35-2.50 (m, 1 H), 2.53-2.80 (m, 3 H), 3.13 (dd, 1 H, J = 3.5, 15.6 Hz, H-4), 3.42 (dd, 1 H, $J = 4.8$, 15.6 Hz, H-4'), 4.05-4.15 (m, 1 H, H-5), 4.28 (ddd, 1 H, $J = 2.8$, 6.5, 10.3 Hz, H-10), 4.95 (dt, 1 H, $J = 3.8$ 5.1, 10.2 Hz, H-10'); 13C NMB (75.5 MHz, CDC13) 8 20.0 (CH2). 29.2 (CH2). 52.8 (C-5). 55.2 (C-4) 63.4 (C-lo), 81.1 (Calkyne), 82.6 (C-alkyne), 83.0 (C-3). 165.8 (C-2).

(3R*,5R*)-3,5-Dichloro-3,4,5,6,9,lO-hexahydro-oxecin-2-one (54): According to the general procedure B, acetate 31 (141 mg, 0.63 mmol) in 6 mL of **benzene was treated** with 0.3 equiv of CuCl(O.19 mmol, 18.8 mg) and 0.3 equiv of 2.2-bipyridine (0.19 mmol, 29.7 mg) and heated in a sealed tube at 175 °C for 8 h. Concentration in vacuo and purification by fc $(1:30)$ afforded cis-54 (18 mg, 0.08 mmol, 13%) as a colourless oil. $R_f(1:10)$ 0.50; IR v 3020, 2955, 2925, 2850, 1730, 1450, 1445, 1370, 1320, 1300, 1275, 1265, 1175, 1160, 1150, 1080, 1035, 990, 920, 845; ¹H NMR (300 MHz, CDCI3) 8 2.00-2.20 (m, 1 H, H-9), 2.35-2.50 (m, 2 H, H-9' and H-6), 2.55-2.70 (m, 1 H, H-6'), 2.63 (ddd, 1 H, $J = 3.2$, 10.8, 15.7 Hz, H-4), 2.77 (dt, 1 H, *J* = 11.9, 13.8 Hz, H-4'), 3.95-4.10 (m, 1 H, H-10), 4.09 (dd, 1 H, *J* = 2.8, 11.4 Hz, H-3), 4.15-4.30 (m, 1 H, H-10'), 4.50-4.65 (m, 1 H, H-5), 5.60-5.75 (m, 1 H, CH=), 5.86 (dt, 1 H, *J* = 4.1, 10.8 Hz, CH=); ¹³C NMR (75.5 MHz, CDC13) δ 25.6 *(CH2), 33.1 (CH2), 43.0 (C-4), 53.9 (CHCl), 57.7 (CHCl), 63.3 (C-10), 127.4 (CH=), 127.5 (CH=), 169.1 (C-2); MS (EI, 70 eV)* m/z (relative intensity) 222 (M⁺, 5), 192 (7), 186 (9), 160 (16), 157 (23), 151 (16), 150 (53), 116 (15), 105 (9), 93 (31), 81 (34), 80 (37), 79 (29), 67 (100), 55 (30), 41 (29), 39 (27); HRMS calcd for C9H13O2Cl2 (M⁺+1) 223.0293, found 223.0286.

3,3,5-Tricbloro-3,4,5,6,9,lO-hexahydro-oxecin-2-one (55): According to the general procedure B, acetate 32 $(106 \text{ mg}, 0.41 \text{ mmol})$ in 4 mL of DCE was treated with 0.3 equiv of CuCl $(0.12 \text{ mmol}, 12.3 \text{ mg})$ and 0.3 equiv of 2,2-bipyridine (0.12 mmol, 19.4 mg) and refluxed for 3 days. Concentration *in vacuo* and filtration over a short Si-column (1:10) yielded crude 55 (78 mg, 74%), which was purified by fc (1:30) to afford 55 (38 mg, 0.15 mmol, 37%) as a colourless oil. $R_f(1:10)$ 0.50; IR v 2960, 2930, 2850, 1755, 1450, 1435, 1420, 1370, 1335, 1270, 1255, 1240, 1180, 1070, 1035, 990, 935, 890, 860; ¹H NMR (300 bB-f& Cf)Ct3) 8 2.00-2.15 (m, 1 H, H-9). 2.40-2.55 (m. 1 H, H-9'). 2.44 (dd, 1 H, *J =* 2.8, 10.5 Hz, H-6). 2.75-2.90 (m, 1 H. H-6'). 2.88 (dd. 1 H, *J = 2.9, 14.2 Hz,* H-4). 3.24 (dd, 1 H, *J =* 11.7, 14.2 Ha, H-4'). 3.91 (ddd, 1 H. *J I* 3.0, 10.7, 12.5 Hz. H-10), 4.50-4.60 (m, 1 H, H-5), 4.80 (ddd, 1 H, $J = 1.9$, 5.1, 10.5 Hz, H-10'), 5.65-5.80 (m, 1 H, CH=), 5.90 (dt, 1 H, $J = 5.1$, 10.4 Hz, CH=); ¹³C NMR (75.5 MHz, CDCl3) 8 25.3 (CH2), 31.8 (CH2), 51.5 (C-4), 56.7 (C-5), 65.3 (C-10), 82.0 (C-3), 127.4 (CH=), 127.6 (CH=), 165.0 (C-2).

 $(3R^*, 5R^*)$ - and $(3R^*, 5S^*)$ -3,5-Dichloro-oxa-7-cycloundecyn-2-one (56): According to the general procedure. B, acetate 33 (178 mg, 0.76 mmol) in 7.5 mL of benzene was treated with 0.3 equiv of CuCl (0.23 mmol, 22.5 mg) and 0.3 equiv of 2,2-bipyridine (0.23 mmol, 35.5 mg) and refluxed for 18 hours, later 0.3 cquiv of CuCl was &ted as some starting material was stilt present and the mixture was refluxed for 18 h. Concentration *in vacua and purikation* by fc (1:20) afforded 56 as two separated diastereomers in the ratio of 67:33 in total yield of 51% (90.8 mg, 0.39 mmol). Major isomer of 56: 60.2 mg (0.26 mmol, 34%), colourless oil R_f (1:10) 0.30; IR v 3000, 2935, 2925, 2840, 1730, 1460, 1435, 1385, 1350, 1330, 1315, 1295, 1275, 1260, 1220, 1175, 1155, 1085, 1045, 1010, 905; ¹H NMR (300 MHz, CDCl3) δ 1.85-2.55 (3 x m, 3 x 2 H, 2 H-6, 2 H-9, 2 H-10). 2.55-2.63 (m, 1 H, H-4). 3.05 (ddd, 1 H, *J =* 3.4, 12.2, 15.2 Hz, H-4'). 3.72 (ddt, 1 H, *J =* 3.5, 6.1, 11.4 HZ, H-5). 4.20 (ddd, 1 H, *J=* 2.7.6.6, 11.4 Hz,H-lQ4.33 (dd, 1 H, *J=2.9,* 12.1 Hz, H-3),4.59 (ddd, 1 H, *J=* 2.5, 8.1, ll.OHz, H-11'); 13C NMR (75.5 MHz, CXl3) 6 17.3 (C-10). 26.7 (CH2). 29.5 (CH2). 44.7 (C-4), 54.2 (CHCl), 55.3 (CHCl), 66.4 (C-11). 76.9 (Calkyne). 84.4 (C-akyne), 168.2 (C-2): Minor isomer of 56: 30.6 mg (0.13 mmol, 17%). colourless oil *Rf* (1:lO) 0.25; IB v 2960. 2925.2840, 1740, 1455, 1430, 1385, 1360, 1350, 1335, 1325, 1305, 1290, 1220, 1180, 1170, 1160, 1085, 1040, 1020,990, 905: lH NMB (308 MHx, CDCl3) 8 1.80-2.40 (2 x m, 5 If), 2.49 (ddt, 1 H, *J =* 2.5, 10.3, 16.8 Hz), 2.68 (ddd, 1 H, *J =* 3.0.6.5, 15.1 Hz, H-4). 2.81 (ddd, 1 H, *J =* 4.7, 8.9, 14.9 Hz, H-4'). 4.00 (ddd, 1 H, *J =* 3.0, 8.1, 11.2 Hz, H-11). 4.17 (ddd, 1 H, *J =* 4.5, 7.9, 14.8 Hz. H-5). 4.62 (dd, 1 H, *J =* 3.0, 8.9 Hz, H-3). 4.84 (ddd, 1 H, *J =* 3.0. 6.8, 11.3 Hz, H-11'); l3C NMR (75.5 MHz, CDCl3) δ 16.9 (C-10), 25.9 (CH2), 28.5 (CH2), 42.4 (C-4), 54.3 (CHCl), 55.4 (CHCl), 65.7 (C-11), 76.9 (C-alkyne), 84.5 (Calkyne), 168.6 (C-2).

3,3,5-Trichloro-oxa-7-cycloundecyn-2-one (57): According to the general procedure B, acetate 34 (193 mg, 0.72) mmol) in 7.2 ml of DCE was treated with 0.3 quiv of CuCl (0.21 **mmol,** 21.3 mg) and 0.3 equiv of 2,2-bipyridine (0.21 mmol, 33.6 mg) and heated at 175 'C for 3 hours. Concentration *in vacua* and purification by fc (1:20) to afforded 57 (20.1 mg, 0.075 mmol, 10%) as a colourless oil. *R_f* (1:10) 0.40; IR v 3030, 3000, 2960, 2930, 2840, 1745, 1590, 1460, 1430, 1415, 1385, 1360, 1350. 1330, 1320, 1295, 1280, 1235, 1190, 1170, 1080, 1070, 1045, 1030,995,890; 1H NMB (200 MHz, CDC13) 8 1.85-2.60 (3 x m. 3 x 2 H, 2 H-6, 2 H-9 and 2 H-10). 3.01 (dd, 1 H, *J =* 5.7. 15.6 Hz, H-4). 3.49 (dd, 1 H, *J =* 3.1, 15.7 HZ, ~-4'). 3.75- 3.90 (m, 1 H, H-11), 4.15-4.40 (m, 1 H, H-11'), 4.75 (ddd, 1 H, *J* = 3.3, 7.3, 11.1 Hz, H-5); ¹³C NMR (63 MHz, CDC13) 8 17.4 (C-10), 26.6 (CH₂), 29.4 (CH₂), 53.9 (C-4), 54.1 (C-5), 68.6 (C-11), 76.7 (C-alkyne), 83.1 (C-alkyne), 83.7 (C-3), 164.8 (C-2).

REFERENCES

- 1. (a) Guillerm, D.; Linstrumelle, G. Tetrahedron Lett. 1985, 26, 3811. (b) Tabuchi, T.; Kawamura, K.; Inanaga, J.; Yamaguchi, M. *Tetrahedron Lett. 1986.27.3889. (c) Yvexgnaux,* F.; Le Floc'h, Y.; Gr&, R.; Toupet, L. *Terrahedron Len. 1989,30,7393.* (d) Ishida, M.; Muramaru, H.; Kato, S. *Synthesis 1989,562. (e) Matsuyama,* H.; Nakamura, T.; Kamigata, N. J. Org. Chem. 1989.54.5218. (f) Petasis, N. A.; Patane, M. A. J. *Chem. Sot. Chem. Comm. 1990,836. (g)* Kaino, M.; Naruse, Y.: Ishihara, K.: Yamamoto, H. J. Org. *Chem.* 1990.55, 5814. (h) Hirano, K, Oose, M.: Morimoto, T. *Chem. Lerr.* 1991. 331. (i) Carling, R. W.: Clark, J. S.: Holmes, A. B. J. *Chem. Sot. Per&in Trans. I 1992, 83. (i)* Simonot, B.; Rousseau, G. *Tetrahedron Len. 1993,34,4521.*
- *2.* (a) Vesonder, R. F.; Stcdola, F. H.; Wickerham, L. J.; Ellis, J. J.: Rohwedder, W. K. *Con. J.* Chem. 1971,49,2029. (b) Ishida, T.; Wada. K. J. *Chem. Sot. Chem.* Comm. 1975,209. (c) Nagumo, S.; Suemune, H.; Sakai, K. *Tetrahedron Lerr. 1991,32,5585.* (d) Tapiolas, D. M.; Roman, M.; Fenical, W. J. *Am. Chem. Sot.* 1991,113,4682. (e) Zeeck. A. *Eur. Pot. 0 497 300* Al, 1992. (f) Fang, X.-P.: Anderson, J. E.: Qiu, X.-X.; Kozlowski, J. F.; Chang, C.-J.: McLaughlin, J. L. *Tetrahedron 1993,49, 1563. (g) Congreve,* M. S.; Holmes, A. B.; Hughes, A. B.; Looney, M. G. *J. Am.* Chem. Sot. 1993.Il5.5815. (h) Buszek, K. R.; Sato, N.; Jeong, Y. *J. Am.* Chem. Sot. 1994,116, 5511.
- *3.* (a) Porter, N. A.; Chang, V. H.-T. *J. Am. Chem. Sot. 1987,109.4976.* (b) Porter, N. A.; Lather, B.; Chang, V. H.-T.: Magnin, D. R. *J. Am. Chem. Sot. 1989,111,8309. (c)* Hitchcock, S. A.: Pattenden, G. *Tetrahedron Lert. 1990,31, 3641.* (d) Baldwin, J. E.; Adlington, R. M.; Mitchell, M. B.; Robertson, J. J *Chem. Sot. Chem. Comm. 1990, 1574. (e)* Boger, D. L.; Mathvink, R. J. *J. Am. Chem. Sot. 1990,112,4008. (f)* Snider, B. B.; Merritt, J. E. *Tetrahedron* 1991, 47,8663. *(g) Klaus, G.* A.: Wu, Y. *J. Am. Chem. Sot. 1992.114.8705.* (h) Lee. E.: Yoon C. H.; Lee, T. H. *J. Am.* Chem. Sot. 1992,114, 10981. (i) Yamamoto, T.; Ishibuchi, S.; Ishizuka, T.; Haratake, M.; Kunieda, T. *J. Org.* Chem. 1993,58, 1997. (i) Feldman, K. S.; Berven, H. M.: Romanelli, A. L.; Parvez, M. *J. Org.* Chem. 1993,58,6851. (k) Molander, G. A.; McKie, J. A. *J. Org.* Chem 1994.59.3186.
- *4.* (a) Nagashima, H.: Seki, K.; Ozaki, N.; wakamatsu, H.; Itoh, K.; Tomo, Y.;Tsuji, J. *J. Org. Chem. 1990,55,985. (b)* Nagashima, H.; Ozaki, N.; Ishii, M.; Seki, K.; Washiyama, M.: Itoh, K. *J. Org.* Chem. 1993,58,464.
- *5.* (a) Asscher, M.; Vofsi, D. J. Chem. Soc. 1963, 1887. (b) Hayes, T. K.; Villani, R.; Weinreb, S. M. J. Am. Chem. Soc. 1988,110, *5533. (c)* Nagashima, H.; Wakamatsu, M.; Ozaki, N.; Ishii, T.; Watanabe, M.; Tajima, T.; Itoh, K. *J. Org.* Chem. 1992,57, 1682. (d) Ishibashi, H.; Uemara, N.; Nakatani, H.; Okazaki, M.; Sato, T.; Nakamura, N.; lkeda, M. *J Org. Chem. 1993,58, 2360.*
- 6. (a) Bellus, D. Pure *and Appl.* Chem. 1985,57, 1827. (b) Martin. P.; Steiner, E.; Streith, J.: Winkler, T.; Bellus, D. *Tetrahedron 1985,41,4057. (c)* Seijas, J. A.: VaZquez-Tato, M. P.; Castedo, L.: Est&.z, R. J.; 6nega. M. G.; Rufz, M. *Tetrahedron 1992.48, 1637.*
- I. (a) Broadhurst, M. D.; Gless Jr., R. D. *Eur. Pot. 0* 129 2% Al, 1984. (b) Broadhurst, M. D.; Gless Jr., R. D. US Pal. 4,645,843, 1985. **(c)** Broadhurst, M. D. US *Pal. 4.132.713; C.A. 1977.90, P137672y.* (d) Rempfler. H.; Meyer, W. *Eur Pal Appl.* EP 55,215: *C.A.* 1982,97, P182204c.
- 8. (a) Lolkema. L. D. M.; Hiemstra. H.; Al Gouch, A. A.; Speckamp, W. N. *Tetrahedron Len. 1991,32, 1491. (b)* Udding, J. H.; Hiemstra. H.; van Zanden, *M. N.* A.: Speckamp, W. N. *Terruhedron Lerr.* 1991.32, 3123. (c) Udding, J. H.; Tuijp, C. J. M.; Hiemstra, H.: Speckamp, W. N. *Tetrahedron 1994.50,* 1907.
- 9. (a) Pimmg, F. 0. H.; Steernan. W. J. M.; Hiemstra, H.; Speekamp, W. N.; Kaptein, B.; Boesten, W. H. J.; Schoemaker, H. E.; Kamphuis, J. *Tetrahedron Lerr. 1992,33,5141.* (b) Pimmg, F. 0. H.; Hiemstra, H.; Kaptein, B.; Martinez Sobrino, M. E.; Petra, D. G. I., Schoemaker, H. E.; Speckamp, W. N. *Synlett 1993,739.*
- 10. Blankley, C. J.; Sauter. F. J.; House, H. 0. Org. *Synth. Coil. 1973.5, 258.*
- 11. Sato, F.: Jinbo, T.; Sato, M. *Tetrahedron Letr. 1980.21, 2171.*
- 12. Penninger, J.: Weyerstahl, P. *Liebigs Ann.* Chem. 1978, 191.
- 13. McConnell, W. V.: Moore, W. H. *J Org. Chem. 1965.30, 3480.*
- 14. Günther, H. J.; Guntrum, E.; Jäger, V. *Liebigs Ann. Chem.* 1984, 15.
- 15. Mazzocchi, P. H.; Wilson, P.; Khachii, F.; Klingler, L.; Minamikawa, S. *J Org.* Chem. 1983.48, 2981.
- 16. Coates, R. M.; Ley, D. A.; Cavender, P. L. *J Org. Chem.* 1978, 43, 4915.
- 17. a) Sevin, A.; Chodkiewicz, W.; Cadiot, P. *Bull. Sot. Chim. Fr. 1974,913.* b) Jeffery, T. *Tetrahedron Lett. 1989.30,*

2225.

- 18. Suzuki, N.; Tsukanaka, T.; Nomoto, T.; Ayaguchi, Y.; Izawa, Y. J. Chem. Soc. Chem. Commun. 1983, 515.
- 19. Barth, F.: O-Yang, C. *Tetrahedron Lell.* 1990.31, 1121.
- 20. (a) Allinger, N. L. Pure and Appl. Chem. 1982, 54, 2515. (b) Anet, F. A. L. In *Conformational Analysis of Medium-Sized Heterocycles, Glass,* R. S., Ed.; VCH: Weinheim, 1988, p 35ff.
- 21. (a) Beckwith, A. L. J.; Schiesser, C. H. *Tetrahedron 1985.41.3925.* (b) Spellmeyer, D. C.; Houk, K. N. J Org. *Chem.* 1987.52, 959.
- 22. (a) Huisgen, R.; Ott, W. *Terrahedron 1959.6.253. (b)* Wiberg, K. B.; Waldron, R. F. J. *Am.* Chem. Sot. 1991,113, 1691.
- 23. Grüssner, A.; Bourquin, J.-P; Schnider, O. *Helv. Chim. Acta.* **1945**, 28, 517.
- 24. Lists of refined coordinates and e.s.d.'s were deposited at the Cambridge Crystallographic Data Centre.
- 25. Oki, M.: Nakanishi, H. *Bull. Chem. Sot. Japan 1970.43.2558.*
- 26. Udding, J. H.: Tuijp, C. J. M.; Hiemstra, H.; Speckamp, W. N. *J. Chem. Sot. Perkin Trans. I/ 1992, 857.*
- 27. a) Bland. W. J.; Davis, R.; Durrant, J. L. A. *J. Organomer. Chem. 1984,260, C75.* b) Bland, W. J.; Davis, R.; Durrant, J. L. A. *J. Organomer.* Chem. 1984,267. C45.
- 28. Still, W. C.; Kahn, M.; Mitra, A. *J. Org.* Chem. 1978.43, 2923.
- 29. Keller, R. N.; Wycoff, H. D. *lnorg. Synrh. 1946.2,* 1.
- 30. Korhonen, 1.0.0. *J. Chromarogr. 1984,288,329.*

(Received in UK 21 July 1994 *revised* 7 *September* 1994; *accepted* 9 *September* 1994)